OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2025-12-31-accounts

Stjohn ofJeru5alem Eye Hospital Group ANNUAL REPORT

TRUSTEES' ANNUAL REPORT

STRATEGIC REPORT

STRATEGY IN ACTION

SAVING SIGHT CHANGING LIVES

St John of Jerusalem Eye Hospital Group is a centre of excellence providing ophthalmic care of high quality to the people of the Holy Land regardless of ethnicity, religion, social class, or ability to pay. We have been treating patients in the region for over 144 years. Our sightsaving work is carried out against challenging odds to the highest international standards.

30 Statement of Compliance with Trustees’ Duties under Section 172 (1)

GOVERNANCE

FINANCIAL STATEMENTS

42 Independent Auditor’s Report

62 Professional Advisors & Administrative Information 63 Thanking Our Supporters

GLOSSARY: IAPB – The International Agency for the Prevention of Blindness; JCI - Joint Commission International; the gold-standard for healthcare worldwide. NGO – non-governmental organisation. NIS - New Israeli Shekel. SJEHG - St John of Jerusalem Eye Hospital Group; this refers to all our entities. SOA - St John of Jerusalem Ophthalmic Association. UNRWA - United Nations Relief and Works Agency, the UN branch responsible for Palestinian refugees. USAID - United States Agency for International Development. WHO – World Health Organisation.

All uncredited photos throughout this Annual Report have been taken by staff of SJEHG. All the images used in this report are of actual SJEHG staff and patients and they have given their consent.

St John of Jerusalem Eye Hospital Group Company no: 7355619, Charity no: 1139527 Registered Office: 4 Charterhouse Mews, London EC1M 6BB

ABOUT ST JOHN OF JERUSALEM EYE HOSPITAL GROUP (SJEHG)

----- Start of picture text -----
Jerusalem Hospital
----- End of picture text -----

The St John of Jerusalem Eye Hospital Group (SJEHG) is a UK-registered charity that delivers sight-saving care in Jerusalem, the West Bank and Gaza. Services are delivered through two registered charities, each operating under local legal frameworks.

In Jerusalem, services are provided by St John Eye Hospital – Jerusalem RA, an Israeli incorporated not for profit entity, operating in Sheikh Jarrah, the Old City (Muristan), and Kufr Aqab.

In the West Bank and Gaza, services are delivered by St John Eye Hospital, a UK-registered charity, also registered as international NGO with the Palestinian Interior Ministry.

For over 144 years, the Order of St John, latterly via its subsidiary SJEHG, has been delivering ophthalmic services in the Holy Land. SJEHG provides care from six sites, plus three mobile outreach programmes (for further information on our services, see the Snapshot of 2025 on page 6).

OUR OBJECTIVES

SJEHG’s “Objects”, as laid out in our Articles of Association, are specifically restricted to the following:

a) The relief of sickness and the protection and preservation of health by providing eye care facilities at the St John Eye Hospital in Jerusalem and at such hospitals and clinics elsewhere as the directors may think fit and the medical and nursing education and medical research activities connected therewith;

b) the support of humanitarian relief anywhere in the world;

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

2

3

The pressing need for ophthalmic services in the Palestinian population

CHAIRMAN & CEO INTRODUCTION

For the first ten months of 2025, the war in Gaza continued, with almost 70,000 people killed since the outbreak of hostilities. In October 2025, a ceasefire agreement was reached and has largely held since then. The war and its impact on the security situation in Jerusalem and the West Bank have presented significant challenges to hospital operations. Despite the Gaza Hospital remaining non-functional for most of 2025, 41,195 patients still received eye care in Gaza in that year.

In the West Bank and Jerusalem, access to eye care was also compromised due to the heightened levels of violence. The war has also impacted the movement of people and goods in the West Bank and hindered

Dr Ahmad Ma'ali & Sir Andrew Cash in the Jerusalem Hospital Gardens

access of patients to the Jerusalem Hospital. In response, management implemented several measures to enhance access to quality eye care. These included the opening of the Nablus Hospital, expansion of services in Kufr Aqab, and the establishment of a community-based child vision screening initiative, as well as strengthening outreach activities to the most isolated communities including the establishment of a third outreach service in the south of the West Bank.

As a result of these efforts, SJEHG’s clinical activities were exceptionally high at almost all sites. In total, 231,968 outpatient visits were conducted which represents a new record for SJEHG. As for major surgeries, 4,550 surgeries were performed across SJEHG.

Despite all the challenges, SJEHG has continued to prioritise training and education for all staff. This has included fellowship training for three medical staff, postgraduate nurse training, and in-house training as well as the medical residency programme.

As for our finances, patient-related income was up by almost NIS 2.4m (£593k) as compared to budget and there were NIS 3.2m (£791k) savings in payroll as well as other expenditures.

Thank you to all our donors who have gone the extra mile to help keep our services running – it is very much appreciated. Thank you also to all St John Priories and Associations for their unwavering support. We would especially like to thank the Priory in the USA of the Order of St. John for their financial contributions which have been instrumental in sustaining and developing our eye care services in the Holy Land.

SJEHG has maintained its quality care and ensured the safety of its patients and staff. The Jerusalem Hospital was re-accredited by JCI for the fifth consecutive time and the Hebron Hospital received its first JCI accreditation.

Future plans include rebuilding service provision in Gaza, expanding surgical services at both the Nablus and Hebron Hospitals, continuing the child vision screening programme, and pursuing income-generating projects across SJEHG.

Whilst we are aware that there may be challenges in our future, we are confident in our ability to rise to these challenges and continue to provide expert eye care to the people of the Holy Land.

Thank you.

HOSPITALLER’S REPORT

The most-recently published of sight loss. However, unlike study on vision loss in the cataract, DR results in structural Palestinian population (2018-2019), changes in the central and also called the Rapid Assessment peripheral areas of the retina. At of Avoidable Blindness (RAAB), best, these can be stabilised to identified three diseases in the prevent progression. Unchecked, adult patient population. Across it can lead to permanent central all degrees of sight loss – from and peripheral retinal damage, mild to complete blindness, as retinal detachment, and collapse defined by 1992 WHO definitions of the eye. – these are refractive error (the need for glasses), cataract, and Children are also at risk of visual diabetic retinopathy. loss due to preventable and

Children are also at risk of visual loss due to preventable and treatable causes, in addition to infrequent inherited and congenital disorders, some of which (such as congenital glaucoma and other developmental anomalies) are challenging to manage. The result of visual deprivation in the first decade of life is ‘amblyopia’, referring to failure of neural development of the ‘sight centre’ in the cerebral cortex. Many eye diseases cause amblyopia, but the leading ones are entirely preventable if treatment is given in the first decade of life. These include refractive error and strabismus (squint), both of which require glasses, frequent repeated examination, and ‘patching’. The latter involves covering the good eye for several hours each day to encourage normal development of the cerebral ‘sight centre’. Where squint persists, this is managed with surgery to prevent subsequent amblyopia.

The first, refractive error, accounted for 45% of all causes of ‘mild visual loss'. It also accounted for 15% of ‘moderate loss’, roughly equating to the ability to see only the first three lines on a standard visual acuity chart. Although other eye conditions frequently coexist, simple diagnosis and the provision of glasses would improve vision in many patients.

The second cause, cataract, cannot be prevented, but modern surgery delivers a marked improvement in visual function. In the Palestinian population, cataract accounts for 45% of all cases of ‘severe visual impairment’ (the inability to see the first line on an acuity chart, or ‘6/60’), and over a third of cases of ‘legal blindness’, so the demand on our services is high. In an ageing population, these figures are set to rise, with over 5,000 Palestinians currently estimated to be ‘legally blind’ for want of surgery. Proficient and safe cataract surgery is vital, because complicated surgery is a cause of visual loss, placing further strain on services already overwhelmed.

Central to tackling these causes of sight loss is one essential concept: eye screening. In a population with reduced access to healthcare, where schools lack eye screening resources, where movement in the West Bank is increasingly restricted, and where transfer of ophthalmic drugs and equipment into Gaza has been limited – in all these cases screening forms a central pillar of SJEHG’s work. Over the past

The third cause of visual loss in this population, and the most pressing given its irreversible nature, is diabetic retinopathy (DR). After cataract, DR is the leading cause of all degrees

two years, SJEHG has undertaken vital primary care screening, and screening of diabetic patients. The other chief causes of adult visual loss – cataract and refractive error – require screening but are not timesensitive. In contrast, DR is, and a central pillar of SJEHG’s strategy in Gaza is to identify and manage these patients, typically with intraocular injections to reduce retinal vascular leakage.

Once the limitations of service delivery in Gaza improve, and with ongoing restrictions in the West Bank, screening for ocular disease becomes more pressing than ever before. Support from the wider family of St John, and all our donors, is immensely appreciated because it directly supports SJEHG in its mission to address preventable eye disease in this population.

Thank you.

Dr David Verity KStJ MD MA BM BCH FRCOphth Hospitaller, Order of St. John

Sir Andrew Cash OBE GCStJ Dr Ahmad Ma’ali KStJ Chairman CEO

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

4

5

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

SJEHG IS CURRENTLY THE MAIN PROVIDER OF OPHTHALMIC CARE IN GAZA

STRATEGIC REPORT

SNAPSHOT OF 2025

We reached 231,968 patients (32% up on 2024), performed 4,550 major surgeries, and employed 284 people[1] across our services*.

JERUSALEM HOSPITAL We treated 57,284 patients in our East Jerusalem Hospital and performed 3,500 major operations.

183 staff members, including 115 medical, allied health and nursing professionals.

MURISTAN CLINIC[4] We treated 51 patients at our Muristan Clinic.

NABLUS HOSPITAL 2

We treated 16,244

outpatients at our Nablus Hospital and performed 264 major surgeries.

KUFR AQAB CENTRE Our Kufr Aqab Centre treated 13,064 patients.

19 staff members including 14 medical, allied health and nursing professionals.

MOBILE OUTREACH

HEBRON HOSPITAL

SERVICES (WEST BANK)[5 ] Our Jerusalem-based Mobile Outreach service in the West Bank screened 15,519 individual patients. Our Nablus-based Mobile Outreach service screened 9,887 patients in the northern West Bank. In November 2025, we launched a third outreach service in the southern West Bank, serving the districts around Hebron and Bethlehem, which screened 1,799 patients.

Our Hebron Hospital treated 17,345 patients and performed 786 major surgeries.

GAZA HOSPITAL

As part of our Emergency Response Plan for Gaza, we treated 41,195 patients in Gaza at a series of semi-static outpatient clinics and, sporadically, at our Gaza Hospital.

24 staff members including 18 medical, allied health and nursing professionals.

CHILD SCREENING

MOBILE OUTREACH PROJECT

SERVICES (GAZA)[3]

Our Child Vision

35 staff members, including 27 medical, allied health and nursing professionals.

The pre-war mobile Screening Programme in outreach service in Gaza Jerusalem and the West has not been operational Bank screened 59,580 since October 8th, 2023. children.

RUNNING COSTS 2025

63%

In 2025, the cost to run our services amounted to £12.4 million, of which 63% was sourced from fundraising. Your support enables our vital services to continue.

Patient income 36% Investment and other income 12%

----- Start of picture text -----
Staff outside
refurbished Gaza
Hospital, May 2025
----- End of picture text -----

SPOTLIGHT ON GAZA

For more than three decades, SJEHG has been the primary provider of specialist eye care in Gaza. Since 1992, our teams have served communities facing deep and persistent hardship. Over the past few years, however, that commitment has been tested as never before.

THE NEED HAS NEVER BEEN GREATER

The most recent RAAB survey paints a stark picture. Before the war, 31.5% of Gazans over 50 lived with some degree of vision loss, and 3.5% were blind - roughly double the prevalence in the West Bank and significantly higher than regional and global averages.

Despite the closure of our main hospital building in Gaza City in October 2023 and repeated evacuations of staff due to insecurity, SJEHG has remained operational in Gaza throughout the conflict. From April 2024, our staff implemented a phased emergency medical response, initially focused on vision screening and essential primary eye care, before expanding to targeted interventions for diabetic retinopathy and other urgent conditions.

Tragically, more than 80% of blindness in Gaza in the 50+ age group is avoidable or treatable, most commonly caused by untreated cataract and diabetic retinopathy.

The conflict has dramatically intensified this burden. While pre-war caseloads were largely routine - cataract, glaucoma,

In 2025, SJEHG treated 41,195 displaced people in Gaza, including 11,738 children, an extraordinary achievement under the most complex humanitarian conditions. For much of this period, SJEHG was the sole dedicated provider of specialist eye care in the territory.

diabetic eye disease and paediatric conditions - we have since seen a sharp rise in:

Thousands of patients receiving long-term care before the war have lost follow-up care, resulting in irreversible sight loss.

Of the patients we treated from April 2024 to the end of 2025, 47% require further investigation or ongoing treatment, and 6,839 individuals (11%) need major sight-saving surgery. Nearly 1,000 patients urgently require Avastin injections for diabetic retinopathy, and hundreds need therapeutic laser treatment. The surgical backlog will take years to address.

~~Deir Al Balah feld clinic~~

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

6 St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

7

~~Mohammed Yaghi undergoing eye examination~~

RETURNING TO OUR HOSPITAL

During a temporary ceasefire, our staff were able to assess damage to our five-storey Gaza City hospital. Limited renovations enabled us to reopen for essential outpatient services in May 2025. Following the ceasefire of October 2025, patient numbers have risen to approximately 1,000 per week across three operational sites:

This level of activity has not been seen consistently since late 2024 and reflects the enormous unmet need. Many patients must travel through damaged infrastructure, often at considerable personal risk, to reach us.

A STORY OF HOPE

When 12-year-old Mohammed Yaghi arrived at our hospital in Gaza City, he had been living in displacement camps after losing his home. Suffering constant pain in his right eye, his family feared the worst.

Diagnosed with severe eye allergies caused by dust exposure, Mohammed received immediate treatment, free of charge. His relief was swift.

For his parents, the reassurance that specialist care remained available offered rare comfort amid uncertainty.

• Commencing cataract surgery to tackle the surgical backlog;

Every patient we see represents a life stabilised, pain relieved, or sight preserved. As Walid Shaqura, Hospital Manager in Gaza, reflects:

“Seeing a child leave our clinic with a smile makes every struggle worth it. Even in the toughest moments, we know the work we do changes lives.”

Throughout the conflict, we have maintained salaries for our Gaza staff and provided hardship payments in recognition of the extraordinary circumstances they face.

WORKING IN PARTNERSHIP

Looking forward, we are developing plans to:

Our ability to continue operating has depended on strong coordination with partners. We are an active member of the Gaza Health Cluster co-chaired by the Palestinian Ministry of Health and the WHO. We work closely with WHO, UK-MED, the Palestinian Red Crescent Society, UNRWA (where permitted) and other local organisations to secure fuel, water, medicines and supplies.

• Relaunch a child vision screening programme in late 2026.

Our previous outreach vehicle organisations to secure fuel, and equipment were destroyed water, medicines and supplies. during the war, significantly limiting access for vulnerable We are also engaging with communities. authorities to facilitate the entry of essential equipment and, in The estimated cost of restoring time, building materials required and rebuilding our Gaza services to rehabilitate our hospital fully.

The estimated cost of restoring and rebuilding our Gaza services over the next five years is £4.5 million.

THE ROAD AHEAD

Even in conflict, sight-saving care cannot wait.

In Gaza today, restoring eye health is not simply a clinical priority, it is a foundation for recovery. The October 2025 ceasefire created limited humanitarian space, but the situation remained fragile. Our immediate priorities are:

Through resilience, adaptability and the unwavering commitment of our staff, SJEHG has continued to preserve sight and provide hope. With sustained support, we can not only meet the immense backlog of need but help rebuild Gaza’s eye health services for the future.

SPOTLIGHT ON NABLUS

The introduction of the Nablus EXPANDING Hospital marked a turning point

in expanding access to quality SURGICAL healthcare for communities in SERVICES the north of the West Bank. In just one year, the hospital has Surgical interventions began in grown significantly in capacity, May 2025, initially offered once services, and patient care.

In March 2025, SJEHG proudly opened its newest day care hospital in the city of Nablus, the commercial and cultural hub of the northern West Bank. Open five days a week from 7am to 3pm, the hospital brings much-needed surgical and specialist services to over 1.2 million people across the six northern governorates of Nablus, Salfit, Qalqiliya, Tulkarm, Jenin and Tubas.

Surgical interventions began in May 2025, initially offered once per week. By January 2026, services expanded to two fixed surgical days per week. The hospital started to operate three surgical days per week from February 2026 to address patient demand, including a waiting list of 400 cataract surgery patients.

BUILDING CAPACITY

The hospital opened with just nine staff members. Within the first year, this has more than doubled to 19, ensuring coverage across all aspects of care.

Bringing the hospital to life wasn’t without its logistical challenges – including security concerns and political unrest preventing contactors from reaching the site as well as supply chain disruptions that delayed the arrival of imported equipment – but thanks to the tireless efforts of SJEHG’s Director of Estates and Support Services Ahmad Awadallah and his team, it became a reality.

A new surgeon has been recruited to meet the increasing demand for surgical interventions, and they commenced performing surgery in January 2026.

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

8 St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

9

NEW CLINICAL SERVICES

Designed and equipped in line with JCI standards, the hospital offers a range of general and subspeciality services including vitreoretinal, glaucoma, cornea, paediatric ophthalmology and oculoplastic clinics.

A Medical Retina Clinic was added in September 2025, providing specialized care for patients with retinal conditions. The hospital’s pharmacy is now fully licensed, ensuring patients have reliable access to prescribed treatments and medications.

~~Reception desk, Nablus Hospital~~

This remarkable achievement would not have been possible without the generosity of our donors and the invaluable support of our partners. Special thanks go to the Australian Government Department of Foreign Affairs & Trade, The Fred Hollows Foundation, The David & Molly Pyott Foundation, the Arab Fund for Economic and Social Development, the St John Priory in the USA, and the Knights Templar Benevolent Fund, whose belief in our mission helped bring this project to life.

PATIENT CASE STUDY

Serria’s Story

Serria Fareeq, a 77-year-old mother of four, lives in the village of Zawatia near Nablus. Over time, she noticed her vision becoming blurry and cloudy, which made her feel uneasy and restricted her ability to leave her home. On many occasions, she found it difficult to recognize faces in her village, a situation that left her feeling embarrassed.

When the SJEHG North Mobile Outreach Clinic visited her village, Serria took the opportunity to have her eyes examined. The medical team diagnosed her with cataracts in both eyes, and a phacoemulsification (Phaco) surgery was scheduled for February 2025 at the main hospital in Jerusalem.

After the surgery on her first eye,

Serria was able to attend a followup appointment at SJEHG's Nablus Hospital in March, which was much closer to her home. The procedure was a success, and her vision has already improved significantly, and she is seeing much more clearly.

Society of Cataract and Refractive Surgeons (ESCRS) for their generous financial support, which helped cover the cost of her surgery. She also thanked the SJEHG team for their professionalism and compassionate care throughout the entire process – from the outreach clinic to the hospitals in Jerusalem and Nablus.

Serria expressed her deep gratitude to the European

THE EYE HEALTH CONTEXT

barriers;

in Palestine resulted in annual productivity losses exceeding US$60 million. Globally, investment in cataract and refractive services is recognised as one of the most cost-effective health interventions, generating significant long-term economic returns.

The RAAB study identified the following as the main causes of blindness and visual impairment amongst the population we serve:

WHY EYE CARE MATTERS

Vision impairment has profound personal and economic consequences. Children with untreated visual impairment face delayed development, lower educational attainment and social exclusion. Adults may lose the ability to work, increasing household poverty and dependence.

The survey also identified certain unique contextual factors which have contributed to avoidable and preventable blindness across the oPt:

Over 5,000 Palestinians are currently estimated to be legally blind for want of surgery

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

10

11

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

STRATEGY IN ACTION

OUR STRATEGY - 2023 2025

The 2023-2025 Strategic Plan was developed through the collaborative efforts of the SJEHG’s Board of Trustees, the senior management team, and staff.

As of 2026, we will be following a new 2026-2028 Strategic Plan. You can find out more about our plans for the future on page 24.

Our Mission:

SJEHG is a centre of excellence providing ophthalmic care of high quality to the people of the Holy Land regardless of ethnicity, religion, social class, or ability to pay.

Our Vision:

SJEHG will work to address avoidable blindness in the Holy Land and be recognised as the leader in the provision of quality eye care in East Jerusalem, the West Bank, and the Gaza Strip.

Our strategy is centred on our CARE values:

• [C][ompassion: Providing ] eye care with empathy and willingness to promote wellbeing;

responsibility for continuous performance & improvement, embracing change & seeking new opportunities to serve;

Our Strategic Aims:

Our strategy outlines how we will continue our mission through six strategic aims:

1. SERVICES:

Provide eyecare which is of the highest quality, accessible and patient centred;

2. CLINICAL DEVELOPMENT:

Lead ophthalmic education, research, and innovation;

3. PEOPLE & STAFF:

Become the employer of choice in our community;

4. TECHNOLOGY & DATA:

Integrate secure technology and data governance with all core aspects of SJEHG’s clinical work;

5. GOOD GOVERNANCE & PARTNERSHIP:

Ensure SJEHG’s good governance and strengthen partnerships, communications, and marketing locally and worldwide;

6. FINANCES:

Ensure financially sustainable services.

It should be noted that our strategy was developed prior to the current war in Gaza. Much of what we had planned, especially in Gaza, will be severely delayed by the current situation.

----- Start of picture text -----
Staff at Hebron Hospital,
November 2025
----- End of picture text -----

SERVICES

Our Aim: Provide eye care which is of the highest quality, accessible and patient centred.

STRENGTHENING SUBSPECIALITY SERVICES AND OUTREACH

During the 2023-2025 period, services were strengthened across SJEHG, including paediatrics, medical retina, cornea, oculoplastic and laser treatment at our Kufr Aqab Centre.

INCREASING ACCESSIBLE QUALITY CARE FOR ALL

We serve a population who face many barriers to care – from physical, such as the separation wall, checkpoints, and blockades, to socio-economic, such as financial constraints or a lack of eye health awareness.

Our outreach services expanded in 2025, with a third outreach team based in Hebron, introduced in November 2025, funded through a generous individual donation and continuing into 2026. This serves a population of around 1 million people residing in the southern districts of the West Bank and has greatly improved our ability to reach some of the most vulnerable communities in Palestine.

Access to our flagship Jerusalem Hospital can be difficult for much of the Palestinian population. To increase access to care, we have adapted our services to help best reach those who need it most. In 2025, we provided care from four hospitals and three clinics across Jerusalem, West Bank, and the Gaza Strip.

In 2025, our West Bank Mobile Outreach teams provided care to over 27,000 beneficiaries – excluding those reached through the Child Vision Screening Programme – accounting for over 11% of all patients seen across SJEHG.

This year, our Jerusalem Hospital was re-accredited by the JCI for another three years, marking over a decade of being recognised as an organisation providing the gold-standard for healthcare worldwide. Our Hebron Hospital also achieved JCI accreditation for the first time in 2025 (inspected alongside our Jerusalem Hospital), a remarkable achievement. We are aiming to bring all facilities to a similar standard as part of our 2026-28 strategy, starting with the Nablus Hospital.

We have also been addressing equity of care by targeting community groups who represent women, children, and people living with disabilities. These groups are more likely to miss out on care, especially as travel is difficult, and our mobile outreach programme has provided excellent means for diagnosis and treatment.

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

12

13

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

ADDRESSING THE GRAVE NEED FOR EYE CARE IN GAZA

The war in Gaza continued into 2025 despite a ceasefire agreement reached in January 2025, which held for almost two months before hostilities resumed across the entire Gaza Strip. Despite ongoing insecurity, our teams in Gaza continued to provide eye care services from multiple locations, including the SJEHG Gaza Hospital, where limited outpatient services resumed in May 2025 after basic renovations. In August 2025, after increased hostilities in Gaza City, our staff were forced to evacuate the hospital once more. However, after the ceasefire agreement in October 2025 we were

Spotlight On: Child Vision Screening Programme

Our Child Vision Screening Programme was first launched in October 2023. The initial phase was funded by the US-based Hilton Foundation, and additional funding from the Priory in the USA of the Order of St John helped ensure the continuation and expansion of vision screening efforts into 2025. The next phase of the screening programme launched in February 2025, backed by a very generous US$500,000 budget from the US Priory, was intended to screen an additional 50,000 children – a target we exceeded in 2025.

The programme was initially designed to provide vision screening for children in Gaza, but in response to the conflict, it was adapted to serve the children of the West Bank, particularly those in refugee camps. In 2025, the Child Vision Screening was conducted by staff from both the Nablus Hospital and Kufr Aqab Centre, as well as the recently established Hebron-based outreach service.

KEY ACHIEVEMENTS:

• Children screened:

59,580 children screened between January and December 2025 – a 72% increase from 2024.

• Referrals for further treatment: Over 7,200 children were referred to SJEHG’s facilities for further treatments, diagnostic procedures, and eyeglasses.

• Community collaboration: We have developed strong partnerships with local schools to enable seamless service delivery and maximise outreach.

able to return to the hospital, and begin renovation work on the two operating theatres, with the aim of resuming surgical services in early 2026.

Securing medical supplies into Gaza remains a challenge, and we work closely with humanitarian organizations including the WHO to ensure shipments of medical equipment and disposables.

We have treated 61,570 patients in Gaza since the start of the war, including 42 patients undergoing surgery, 296 receiving Avastin injections and 296 undergoing LASER treatments. You can read more about our response in Gaza on page 7.

~~Yousef Ammar at new Nablus Hospital~~

BASSAM’S STORY

Bassam Al Zool, a 63-year-old man from the village of Husan near Bethlehem, was struggling with deteriorating vision due to cataracts in both eyes. Once a labourer in the construction industry, he had been unable to work for the past four years due to general health issues, including diabetes and hypertension.

The worsening of his eyesight made daily life incredibly difficult. He could no longer recognize people from a distance and often had to have his wife accompany him to help identify friends and acquaintances. The situation was made even harder by the war, which left his two sons unemployed, further straining the family's financial situation. With no means to afford surgery, Bassam felt helpless.

Thanks to our partnership with ESCRS, Bassam was able to receive Phaco + Intraocular Lens (IOL) cataract surgery from SJEHG. His first surgery was performed at the Hebron branch, while the second eye was treated at the main hospital in Jerusalem.

The outcome was life changing. With his vision restored, Bassam expressed deep gratitude to the hospital team. He was especially relieved to regain his independence in daily activities.

Patient Stories

YOUSEF’S STORY

Yousef Ammar, a 9-year-old boy from the town of Qaffin in Tulkarm (located in the northern West Bank), has been receiving regular eye checkups with SJEHG since 2021.

He suffers from myopia (near-sightedness) and undergoes routine examinations every six months to update his eyeglass (glasses) prescription. He previously used to visit our clinic in Anabta; however, he is now able to access a full range of services at our new Nablus Hospital.

Yousef’s family expressed their gratitude for having a comprehensive eye hospital in Nablus that provides integrated eye care services, including surgeries, to the residents of the northern West Bank.

~~Bassam Al Zool at Hebron Hospital~~

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

14 St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

15

Clinical Development Highlights: 8 medical 8 students 5 articles residents on the in peer reviewed currently specialised publications undergoing Ophthalmic co-authored by training Nursing SJEHG staff programme

CLINICAL DEVELOPMENTS

Our Aim: Lead ophthalmic education, research, and innovation

ADVANCING OPHTHALMOLOGY TRAINING & EDUCATION

Eight medical residents are currently undertaking their four-year speciality programme. One doctor graduated and successfully passed the Palestinian Council examination. One of our medical residents is currently undertaking a two-year sponsored master’s degree in Artificial Intelligence and Health Informatics at the University of Pennsylvania, USA, and will return in June 2026 to resume his work at the Eye Hospital. Another doctor is continuing a neuro-ophthalmology fellowship at Hadassah University Medical Center, as well as another who has completed a short hands-on surgical fellowship in vitreoretinal surgery at Al Ferdaws Eye Hospital in Egypt.

We have also commenced in-house orthoptic assistant training for five optometrists and nurses. This one-year, hands-on training programme is designed to build orthoptic capacity and provide trained personnel to help support services at our Hebron and Nablus Hospitals, as well as the Kufr Aqab Centre.

NURSING

The Sir Stephen Miller School of Nursing at St John Eye Hospital remains the oldest and one of the highest-regarded providers of expert Ophthalmic Nursing Training in the Middle East. Since its establishment in 1998, over 185 specialist ophthalmic nurses have graduated from the school.

The nine-month Specialized Professional Diploma in Ophthalmic Nursing course is fully funded by SJEHG, covering the students’ university fees, stipends, accommodation, food, stationery and other living costs. Both the theoretical and clinical components of the teaching programme

is fully administered at the Jerusalem hospital in partnership with Al-Quds University.

In June 2025, seven students graduated from the School of Nursing. Five of our graduates were employed by SJEHG.

For the current cohort, eight students commenced the Ophthalmic Nursing course in October 2025. Clinically, students are assigned to a rotation training schedule that exposes them to all hospital clinical areas which in turn allows them to apply theory to practice at all levels of ophthalmic nursing practice. Students are closely supervised by their clinical mentors and well supported by the hospital staff. So far, they have gained many skills in ophthalmic nursing and have become more independent in caring for patients in the outpatient clinic, inpatient wards and operating theatre. By the end of January 2026, they will be finishing their Fall Semester.

POSTGRADUATE ACTIVITIES

During 2025, our collaboration with partners from the ERDC (European Retinal Disease Consortium) resulted in the publication of five articles in peer reviewed journals where our medical staff were coauthors.

A total of 66 families with inherited retinal degeneration were recruited to join our genetics research database to reach a total of 843 families since the establishment of the Molecular Genetics Research Laboratory at the Jerusalem Hospital in 2017.

We were also joined by a new genetics' researcher in 2025, who has a master’s degree in genetics and a strong research interest in ophthalmic genetics.

~~2025-2026 Nursing School Cohort~~

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

16 St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

17

~~CEO Dr Ahmad Ma’ali presents Employee of the Year award to Suzanna Majaj, Nurse in Charge, Kufr Aqab Centre (May 2025)~~

Staff Case Study

HANIN SHIHAB

Hanin Shihab, the registration clerk at our Nablus Hospital, has been part of the SJEHG family for nearly ten years, initially based at our Anabta Clinic.

Between 2020 and 2025, the clinic faced an unprecedented challenge due to a marked decrease in patient numbers and reduced demand for services at Anabta. As a result, management was compelled to terminate the contracts of some employees as part of a human resources reorganization. Hanin was among this group, reflecting the magnitude of the challenge we encountered in balancing growing needs with limited resources.

However, with the introduction of the new Nablus Hospital in March 2025, Hanin was reemployed on the first of April 2025 to support the hospital’s transition and resumed her role in the record office as the registration clerk. Hanin’s re-employment shows our commitment to investing in the skills of our staff and providing opportunities in the region.

~~Hanin Shihab at new Nablus Hospital~~

PEOPLE & STAFF

Our Aim: Become the employer of choice in our community

This year has marked significant progress in strengthening our workforce and ensuring we are well positioned to meet evolving organisational needs. A key milestone has been the successful expansion of our services in the new Nablus Hospital, supported by targeted recruitment, structured onboarding, and focused professional development to respond to increasing programme demands. We also launched a new mental health initiative to promote staff wellbeing, resilience, and access to support across all locations.

Recognising that effective communication is fundamental to strong teams, we enhanced internal engagement through the CEO’s regular newsletter and a refreshed HR newsletter, ensuring clearer and more consistent updates on strategy, policy, and people-focused initiatives.

Building on this progress, we have concluded the implementation of the new Grading and Reward

System, introduced succession planning for senior staff, and strengthened our commitment to Equality, Diversity, and Inclusion through the development of a formal EDI log. In addition, we have enhanced staff capability across SJEHG by improving the training framework, with a particular focus on managerial and leadership development for senior staff, especially clinical leaders.

Together, these initiatives demonstrate our continued commitment to investing in our people, strengthening organisational capacity, and fostering a connected, resilient, and highperforming workforce.

In line with the hospital mission and vision to provide the highest quality of eye care services, continuous training remains crucial to ensure our hospital is staffed with highly skilled and knowledgeable nurses & AHPs.

NURSING AND ASSOCIATED HEALTH PROFESSIONALS (AHPS) DEVELOPMENT AND TRAINING

In 2025, the Nursing and AHP department successfully achieved the “Annual Mandatory Training” which is part of the annual continuous professional development. This training strengthens our staff skills and knowledge mainly in patientcentred care, patient safety, infection prevention and communication.

As part of the hospital's preparation for the JCI inspection, the Quality Department conducted intensive staff training on the upgraded policies and procedures outlined in the JCI 8th edition standards. The staff's commitment and strict adherence to the JCI quality standards were instrumental in achieving a successful JCI accreditation in June 2025.

To ensure capacity building, a number of our staff undertook professional training provided by internationally accredited training bodies. Among the certifications awarded were Certified Facility Safety Officer, Certified Medication Safety Officer, Certified Professional in Infection Control, and Certified in Healthcare Performance Improvement. Through such professional growth development, we are consistently building a highly skilled workforce capable of meeting our patients’ expectations and the requirements of the local Ministry of Health.

Newly employed staff are supported through a structured orientation and induction programme, ensuring they are appropriately supervised and equipped with the skills and knowledge needed to safely and confidently commence their roles. Training covers essential clinical and non-clinical areas, including safeguarding children, violence prevention, infection control, health and safety, and communication.

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025 19

18 St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

TECHNOLOGY & DATA

Our Aim: Integrate secure technology and data governance with all core aspects of SJEHG’s clinical and administrative work.

----- Start of picture text -----
Patient registration desk,
Hebron Hospital
----- End of picture text -----

The year 2025 was marked by significant technological advancements and strategic achievements for SJEHG.

the new Priority ERP system. This enterprise system will manage core business operations including procurement, finance, inventory control, and store management.

EFFICIENT DATA MANAGEMENT

The ERP implementation project is fully managed and led by the IT Department, ensuring a smooth deployment, strong coordination across departments, and successful operational integration.

Every day, our systems process patient data, such as demographic information, medical history, treatment plans, billing details.

This year, we successfully completed a major upgrade of our Jerusalem Data Centre, deploying new hardware and modernized software systems to improve performance, reliability, and scalability.

IMPROVED PATIENT CARE AND COLLABORATION OF MEDICAL STAFF

It is essential that relevant staff members have access to reliable and up to date patient information, so they can track patient progress, monitor their treatment plan, and identify any potential health risks.

In addition, our network infrastructure was strengthened through the upgrade and deployment of new firewalls and switches, significantly enhancing data security, system accessibility, and operational resilience across SJEHG. These investments are not merely technical, they are fundamental to safeguarding patient data, ensuring continuity of care, and enabling future innovation.

Since 2023, we have invested in our Picture Archiving and Communication System (PACS), which enhances the management of diagnostic images. This not only reduces the reliance on physical documents but also provides technicians and doctors with a more efficient and organized tool for accessing and managing diagnostic images.

IMPROVED ADMINISTRATIVE FUNCTIONALITY

Administrative tasks, such as appointment scheduling, billing, and insurance claims processing, take up a lot of time and resources, requiring streamlining.

Patient information can be accessed from any site, no matter where the patient was diagnosed. This gives our staff across the different facilities the ability to collaborate on treatment plans.

One of the most important milestones of 2025, leading into 2026, is the ongoing deployment of

----- Start of picture text -----
38%
2%
Patient
Governance
Related
Income
6%
21% 92% Cost of
37% Priory Charitable Generating
Other Income Activities Funds
Voluntary
Income
4%
----- End of picture text -----

FINANCES

Ensure financially sustainable services

----- Start of picture text -----
4%
Investment &
Other Income
----- End of picture text -----

STATEMENT OF FINANCIAL ACTIVITIES

Incoming Resources:£14m 2025
£000
2024
£000
$000
2025
$000
2024
%
2025
%
2024
Patient Related Income 5,388 4,425 7,112 5,664 38 32
Priory Income 2,876 3,332 3,796 4,265 21 24
Other Voluntary Income 5,217 5,587 6,886 7,151 37 40
Investment & Other Income 559 573 738 733 4 4
Total 14,040 13,917 18,533 17,813 100 100
Resources Expended: £12.4m 2025
£000
2024
£000
2025
$000
2024
$000
2025
%
2024
%
Charitable Activities 11,447 9,657 15,110 12,361 92 93
Cost of Generating Funds 754 585 995 749 6 5
Governance & Other Expenditure 217 185 286 237 2 2
Total 12,418 10,427 16,392 13,347 100 100

Thanks to the continued support of our donors, we can provide high-quality charitable eye care to hundreds of thousands of people each year.

The communities we serve need sustainable services. Ensuring that we have the finances to continue to function and invest in key areas is essential. Central to this aim is to continue to diversify our sources of income, while continually seeking ways to control costs and increase efficiency across SJEHG.

We communicate with the Priories to showcase the impact of their donations, such as many of the salaries of our key clinical teams as well as providing support to our most vulnerable patients to access care.

Institutional donations from a variety of sources – both international and specific to the Middle East region are of increasing importance too. These donors invest in multi-year programmes which help to strategically develop our infrastructure and services. We aim to continue to foster further support from these sources.

Patient income through private payments from those who can afford it, as well as medical insurance payments from the health systems in Israel and the West Bank, is a vital part of our sustainability. While patient-related income has not yet reached our longterm sustainability target of 55%, the systems and strategies to support growth are now in place.

The charitable support we receive from Priories, institutions, foundations and individuals combined is the bedrock of our organisation. Without it, we simply could not run our vital services to those most in need. Thank you.

To ensure financial sustainability, cost control measures and efficiency plans generated meaningful savings, tighter expenditure oversight was introduced, and non-patient income streams, including rental and service-related revenue, were strengthened.

For more information on our major donors for 2025, please see page 63.

Grants and donations make up the remainder of our funding. Our St John Priories have been the backbone of our funding since our establishment in 1882, and they make up around 21% of our total income.

We also maintain a high level of reserves to ensure financial sustainability; more details can be found on page 39.

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

20 St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

21

GOOD GOVERNANCE & PARTNERSHIPS

Our Aim: Ensure good governance and strengthen partnerships, communication, and marketing locally and worldwide.

ST JOHN FAMILY:

We are a proud, founding member of the Order of St John. Being a founding member of one of the world’s biggest providers of healthcare gives SJEHG access to partnership with the Order of St John, Johanniter International and the Alliance of the Orders of St John. Together, and alongside several other international bodies, we collaborate on best practice for clinical governance, sustainability and more.

The Order aims to regionalise its services, and we plan to play a key role in the development of the Order’s Europe, Middle East, and Africa regions.

TECHNICAL SUPPORT & GRANT PARTNERSHIPS: There are several other development organisations which collaborate with SJEHG on eye health projects across Palestine. We rely on their expertise or influence to deliver our services at the highest level. Several of these bodies are also donors, to see a full list of major donors go to page 63.

QUALITY &

TRANSPARENCY:

Through our commitment to quality eye care, we have been accredited by the ISO 9001:2015 (Accreditation for Quality Control) and JCI and are subject to regular external audits to ensure that we are adhering to their gold-standard for quality healthcare. We take transparency very seriously, following all UK guidelines to ensure both our accounting and fundraising practices are operating to the correct level. As such, we are registered with official charity bodies in the UK and are independently audited each year. To see our full fundraising statement, see page 35. To see our Independent Auditors' report from PwC see page 41.

LOCAL PARTNERSHIPS: Our strategic partnerships with local health networks are vital to ensure an integrated approach to eye health. We have a Memorandum of Understanding in place with the Palestinian Ministry of Health in both the West Bank and Gaza, to guarantee patients who present with eye conditions at general clinics are referred to us for specialist treatment.

TRAINING:

Both our Sir Stephen Miller School of Nursing and our Medical Residency Programme are locally accredited by Al Quds University, ensuring that our staff are trained to the highest possible standard. Our medical team benefit from opportunities to train in subspecialties internationally and regularly collaborate on medical research with their cohort across the globe. This collaboration has been encouraged by the St John Ophthalmic Association (SOA).

DIGITAL COMMUNITY BUILDING:

To better network and provide accessibility we aim to expand our digital presence. Our revamped English website launched in March 2026, and we will be developing an Arabic website, as well as developing our marketing and communications strategy. These tools will undergo regular monitoring and evaluation to ensure they are best serving all our stakeholders.

~~Roza Jarban~~

Spotlight on Partnership:

The European Society of Cataract & Refractive Surgeons (ESCRS)

Founded in 1991, ESCRS is dedicated to advancing education and research in implant and refractive surgery while fostering the study and practice of ophthalmology. The organisation supports and promotes research, as well as funding projects across the world, including at SJEHG.

Seeking help, she visited the SJEHG clinic in Anabta, located in the northern West Bank. After a full examination, she was diagnosed with combined forms of age-related cataract in both eyes.

Phaco (cataract) surgery for her right eye was scheduled for January 2025. The procedure went smoothly, and after a successful follow-up, her second eye was operated on in March.

One beneficiary of ESCRS’ funding is Roza Jarban, a 74-year-old mother of six, who has spent most of her life in the Tulkarm Refugee Camp. Since the beginning of 2025, she and her family were displaced due to ongoing military operations in the camp. They now live with relatives in another part of Tulkarm, after being forced to leave both their home and the small family business that supported them.

Now, Roza says she feels a real difference. Her vision is much clearer, and she moves around with more ease and confidence. Her son smiles, noting that “she sees even better now than she did before the cataracts began.”

The family expresses deep gratitude to SJEHG and the European Society of Cataract and Refractive Surgeons (ESCRS), who covered the cost of the surgeries. With their financial situation severely impacted by the displacement and loss of income, they say the support made a huge difference at a difficult time.

A few months ago, Roza noticed that her vision was becoming increasingly blurry. Tasks that were once routine – moving around the house, preparing meals, or helping her grandchildren – became difficult and even unsafe.

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

22

23

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

OUR PLANS FOR THE FUTURE

As we conclude our 2023–2025 Strategic Plan and enter a new three-year phase (2026–2028), we do so with clarity of purpose, strengthened systems, and an unwavering commitment to addressing avoidable blindness across East Jerusalem, the West Bank and Gaza.

The past few years have tested us profoundly. The war in Gaza disrupted services, damaged infrastructure, and placed immense strain on patients and staff alike. Yet even in these circumstances, SJEHG treated almost 232,000 patients in 2025 and performed 4,550 major surgeries across our sites. In Gaza alone, more than 65,000 patients were treated during the conflict period, despite severe operational limitations.

This resilience now underpins our vision for the future, building on strong foundations from 2023-2025.

Strategic Plan 2026-2028

Our 2026–2028 Strategic Plan is grounded in evidence, notably the RAAB survey conducted by SJEHG and in the lived realities of our communities.

Cataract, diabetic retinopathy, refractive error and glaucoma remain leading causes of blindness in the region. Contributing factors include poverty, limited access to services, fragmentation within the health system, and the long-term consequences of political instability. The war in Gaza has further intensified demand and deepened inequities.

Our response is clear: expand access, strengthen quality, and rebuild where services have been disrupted.

Expanding and Embedding Quality of Services

A central ambition of the new strategy is to increase the number of patients treated annually from 230,000 to 250,000 by 2028, while maintaining the highest clinical standards.

In Nablus, we will embed JCI standards and work towards full accreditation in 2028. Surgical capacity will be expanded significantly, including the introduction of retinal, oculoplastic and paediatric surgical services. Increasing surgical uptake in

~~Upgraded facilities at Kufr Aqab Centre, April 2026~~

Nablus by 50% is a key target, ensuring that more patients can access specialist care closer to home. At Kufr Aqab and Hebron, services will continue to grow, with targeted increases in subspeciality provision and outreach activity. The child vision screening programme will be sustained and expanded, and additional orthoptic assistants trained to strengthen paediatric pathways across multiple sites.

Across all hospitals and clinics, we will maintain three-year equipment plans, modernise clinical spaces, and implement a reviewed care model with greater emphasis on day care provision, improving patient experience and operational efficiency.

~~Young patient at refurbished outpatient department, Gaza, June 2025~~

Strengthening Organisational Sustainability

Clinical excellence must be matched by financial sustainability.

The 2026–2028 plan sets out clear objectives to enhance both service-related and voluntary income. These include strengthening refractive surgery income, modernising rental accommodation to increase revenue, implementing a SJEHG investment strategy, and expanding incomegenerating initiatives such as pharmacy and facility projects.

The London Office will execute a comprehensive fundraising plan, while relationships with St John Priories and international partners will be deepened through intentional communication and active stewardship. Recent years have demonstrated the strength of partnerships with organisations such as the WHO, Christian Blind Mission (CBM), Malteser International and governmental donors. These alliances will continue to be vital.

Financial resilience is not simply about growth; it is about independence, predictability and the ability to invest in long-term capacity.

Rebuilding & Reimagining Gaza

The future of the SJEHG cannot be considered without addressing Gaza.

The Gaza Hospital, partially damaged during the war, is currently providing limited outpatient and outreach services following partial restoration. The new strategy commits to playing a leading role in rebuilding shattered health services post-conflict.

Subject to funding and security developments, we will develop a comprehensive business plan to renovate, restore and re-equip the hospital to pre-war standards. Outreach services to displaced communities will be sustained and strengthened.

Staff capabilities will be enhanced, and clinical standards embedded in preparation for future JCI accreditation.

The need will not diminish. The demand for ophthalmic services is expected to rise significantly in the post-war period. Our responsibility is to be ready.

Governance, Leadership and Reputation

Strong governance remains foundational. The Board of Trustees and Senior Leadership Team will continue to review performance against strategic milestones at defined intervals, ensuring accountability and adaptability.

Data governance standards will be implemented across SJEHG, compliance with international best practice maintained, and marketing and communications strengthened to enhance global reputation.

The recent redevelopment of the Englishlanguage website, alongside plans to develop the Arabic site, reflects our commitment to transparency, accessibility and engagement with supporters worldwide.

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

24

25

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

FINANCIAL REVIEW: Achievements and Performance in 2025

Investing in People & Innovation

Looking Ahead

The future of the Hospital is not defined solely by expansion, infrastructure or financial targets. It is defined by purpose.

The future of the Hospital rests on its people. We aim to be the employer of choice for eye care in the region. The new strategy commits to leadership development, structured succession planning, expanded training requirements, strengthened equity and inclusion practices, and mental health and safety support for staff working in challenging environments.

In a region marked by instability, SJEHG remains a constant: a centre of excellence providing compassionate, patient-centred eye care to all who need it.

Clinical development remains central. We will sustain medical residency training, pursue academic partnerships, and strengthen research capability, including investment in high-level research leadership. Artificial Intelligence(AI) and digital innovation will be explored to enhance patient communication and enable remote consultations where appropriate.

The next three years will require resilience, discipline and innovation. But they also offer opportunity to rebuild in Gaza, to embed excellence in Nablus, to expand outreach, and to strengthen sustainability across SJEHG.

Above all, they offer the opportunity to ensure that preventable blindness does not determine a person’s future.

In a conflict zone, education and research are acts of long-term confidence. They signal permanence, credibility and ambition.

----- Start of picture text -----
SJEHG staff at the 2025
Staff Awards in Jerusalem.
----- End of picture text -----

For the year ended 31 December 2025, incoming resources amounted to £14m, (2024, £13.9m) while resources expended amounted to £12.4m (2024, £10.4m). This resulted in a surplus of £1.6m (2024, £3.5m) before taking into account realised and unrealised gains on investments of £1.3m (2024, £0.8m) and exchange gains of £0.5m (2024, exchange losses of £0.1m). Overall fund balances accordingly increased by £3.4m in the year (2024, £4.3m).

During the year, patient-related income increased especially our work with the Israeli Sick Funds and the establishment of our new centre in Nablus. Within voluntary income, donations from St John Priories decreased from £3.3m in 2024 to £2.9m in 2025.

Expenditure on charitable activities amounted to £11.5m (2024, £9.7m), being 92% (2024, 93%) of total resources expended. These costs include running the operational hospitals in Jerusalem, Hebron, Gaza, and Nablus, the Muristan Clinic, Kufr Aqab Centre and three operational Mobile Outreach Units, the cost of teaching and training during the year for doctors, nurses and allied health professionals, and the running costs of the genetics laboratory and the refractive suite. The expenditure on charitable activities is primarily personnel costs which makes up 58% of the total cost (2024, 63%). Operating costs were contained through the continuation of enhanced cost controls introduced in earlier years as well as the actions taken by trustees and management to seek to minimise the financial impact of the unstable political

situation in the region. of debt impacts on SJEHG’s cash flows and it is ameliorated, Costs of generating funds to a certain extent, when the constituted 6% (2024, 5%) of European Union and USAID total resources expended and pay a substantial part of the are the costs of the LondonPalestinian Authority outstanding based fundraising team and the debt. Conversely, SJEHG benefits Jerusalem-based fundraising from the receipt of voluntary and projects team, in addition to income, in particular for restricted carrying out various fundraising purposes, in advance of the events. Governance costs related expenditure, usually for amounted to 2% (2024, 2%) of the capital projects. total resources expended and reflect the international nature After the cessation of hostilities, of the charity’s activities and SJEHG was able to reoccupy governance arrangements. the hospital building in Gaza.

After the cessation of hostilities, of the charity’s activities and SJEHG was able to reoccupy governance arrangements. the hospital building in Gaza. During 2025, we managed to Total voluntary income conduct basic renovations to the decreased to £8.1m (2024, £8.9m) outpatients’ clinical area which representing 58% (2024, 64%) allowed us to screen and treat of the incoming resources. patients. Also, during the first Donations included £0.3m (2024, quarter of 2026, SJEHG managed £0.4m) restricted for capital to renovate the hospital’s theatres projects and medical equipment, and resumed operations in March in addition to £2.9m (2024, subject to the availability of £3.3m) donated by the Priories medical supplies. of The Order of St John. Overall, the value of capital projects The investment portfolio is held completed during the year as a means of earning income amounted to £0.3m (2024, £1.2m). to support operational activities

The investment portfolio is held as a means of earning income to support operational activities and as reserves to ensure that SJEHG can continue to fulfil its charitable objectives, in addition to covering the end of service benefits to our staff per local statutory requirements, while maintaining the real value of capital over the medium to long term. The investment objectives include aiming for lower volatility than equity markets, higher diversification and only a modest exposure to illiquid assets. The Investment Committee reviews the portfolio’s strategy and performance with the investment manager on a regular basis.

Funds generated from charitable activities (mainly patient income) amounted to £5.4m (2024, £4.4m) and constituted 38% (2024, 32%) of total incoming resources. The remaining 4% (2024, 4%) incoming resources related to income from investments. During 2025, the Palestinian Authority has been facing major financial difficulties that have resulted in the inability of its Ministry of Health to make sufficient, regular and timely payments to SJEHG. Additionally, due to the political unrest within the region especially after 7th October 2023, and war between Israel and Iran, there are doubts about the ability of the PA to continue paying SJEHG on a regular basis. Funding this level

RESERVES

At 31 December 2025, SJEHG had total funds of £31.8m (2024, £28.4m). This comprised permanent endowments of

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

26

27

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

FINANCIAL REVIEW:

Achievements and Performance in 2025

£3.5m (2024, £3.2m), £0.8m of the NIS, and by changes to (2024, £0.7m) in restricted the statutory level of minimum income funds, and £27.5m (2024, wages in Israel which increased £24.5m) in unrestricted reserves, staff cost by 2%. SJEHG relies of which £13.2m (2024, £12.8m) is heavily on voluntary income available to meet the operating received mainly from donors needs of SJEHG. in the Middle East, Europe, the United Kingdom, and the United RESERVES POLICY States. In the current global The Board of Trustees reviews financial situation, it remains a annually the need for reserves great challenge to continue to in line with the guidance issued attract core funding from existing by the Charity Commission and new sources. The fundraising and considers that, in the strategy includes a focus on context of the geographical endowment and legacy giving in (e.g. earthquakes), political order to mitigate this risk as well and economic situation in the as a focus on major gifts for core region in which SJEHG operates, costs and capital projects. unrestricted reserves need to be Operationally, patient and staff maintained, when circumstances access to Jerusalem is crucial to allow, to equate to at least 18 the continuation of our ability to months running costs (equivalent provide eye care services in the to £20.6m based on 2026 occupied Palestinian territories. operational budget) to ensure To reduce the impact of this, that SJEHG can continue to run SJEHG has opened a new day efficiently with adequate working care hospital in Nablus which capital. It is intended to achieve is accessible to patients in the this through a continuing focus Northern part of the West Bank. on improving efficiency, revenue Moreover, we expanded our generation, the introduction services in the southern part of new sources of revenue, and of the West Bank through the enhanced fundraising activity establishment of a new outreach in order to ensure financial service within Hebron governate. resilience and sustainability for Working in a volatile region has the future. inherent risks. Gaza has its own risks. Also, the war between Israel PRINCIPAL RISKS and Iran has a particular current AND UNCERTAINTIES concern.

PRINCIPAL RISKS AND UNCERTAINTIES

A comprehensive risk

The Clinical Governance

management policy is in place with a risk register of all clinical, operational, financial, external, political and governance risks. The risk register is regularly reviewed by the relevant committees and the Board, with particular focus on residual risks. A key risk which SJEHG faces continues to be financial. The position has been exacerbated by the political situation in the region, the impact of the continued strength of value

Committee continues its regular review of all medical and nursing policies and protocols in addition to instigating and reviewing clinical audits and investigating clinical complications and 'near misses.'

The Board engages independent firms of accountants to carry out internal audit programmes on the financial controls in operation within SJEHG’s activities.

FINANCIAL RISK MANAGEMENT

Liquidity is a recurring issue, especially with the prolonged payment pattern of the PA due to its operational needs. SJEHG therefore sets aside a portion of the investment portfolio in readily realisable assets, in order to ensure operational needs can be met.

International currency exchange movements are an additional risk. It should be recognised that exchange gains do not represent realisable income which are capable of being utilised by SJEHG (the same is true for exchange losses), as they largely reflect the translation into sterling of the NIS value of the Hospital premises. Wherever possible purchasing commitments are made to suppliers in the currency of the source of funding for that expenditure, which is usually US Dollars.

GOING CONCERN

The Trustees must satisfy themselves as to SJEHG’s ability to continue as a going concern for a minimum period of 12 months from the date of approval of the financial statements.

The Trustees have produced detailed, yet adaptable, business plans that consider SJEHG’s forecast and projected activity, the related financial budgets, cash flows and liquidity for the period to December 2027.

The Trustees have also considered in their assessment of going concern the impact of a challenging, yet reasonably plausible, downside scenario (sensitivity analysis) on SJEHG’s liquidity position. Under this scenario, SJEHG projects to have sufficient liquidity through

For these reasons, the Board of Trustees have adopted the going concern basis of preparation of the financial statements.

the period to December 2027, without needing to implement mitigating actions.

For these reasons, the Board of summarise the key points Trustees have adopted the going to an understanding of the concern basis of preparation of complexities and vulnerabilities the financial statements. of SJEHG's financial position. More detailed information is set REMUNERATION POLICY out below, but the key features All roles within SJEHG are which can obscure the financial evaluated in order to determine difficulties/pressures on the where they fit on our pay scale. operating budget are: The salaries within the scale are determined by the market • Capital donations are treated rates for an equivalent position. as income (in accordance with Each year, the payroll budget is the Charities Statement of reviewed, based on legislative, Recommended Accounting statutory and market changes, Practice); using a range of sources and taking account of affordability, all • Exchange rate variations: these as part of the annual budgetary have recently arisen mainly process. from the strengthening of

Nevertheless, the Trustees

have sought to identify certain mitigating actions that could be implemented, in order to provide additional liquidity or reduce cash outflows, so as to ensure that SJEHG can maintain sufficient liquidity over the period to December 2027 – maintaining a balance between supporting the activity that is crucial to delivering the objects of the charity, whilst ensuring the long-term financial sustainability of SJEHG.

Further details of the above are set out in Note 1 to the Financial Statements.

Management consult with the

Statements. Finance, the Human Resources, and the Pay and Remuneration Having assessed the combination Committees of the Board, and a of all these various matters, pay review proposal is submitted the Board of Trustees have a to the Board, which makes the reasonable expectation that decision on the proposal. Staff SJEHG has adequate resources to costs are set out in note 6 of the continue in operational existence financial statements. for the period to December 2027, being a period of at least 12 GUIDE TO SJEHG’S months from the date of approval FINANCES of the financial statements. The aim of this note is to

TABLE OF ADJUSTMENTS 2025

----- Start of picture text -----
|||| |---|---|---| |in £'000|2025|2024| |Net movement in funds per Statement of Financial Activities|3,361|4,315| |Reconciling Items| |Donations for capital projects|(282)|(405)| |Increase in fair value of Investments|(1,254)|(757)| |Exchange gains on translation of overseas operations|(485)|(68)| |Impairment| |Adjusted Net operating results|1,340|3,085| |Less: Outstanding restricted income|(740)|(571)| |Actual Adjusted Net operating results|600|2,514|

----- End of picture text -----

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

28

29

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

STATEMENT OF COMPLIANCE

with Trustees' Duties under Section 172(1)

For the 2025 financial year we are required to report on how the Board of Trustees has complied with its duty under section 172 of the UK Companies Act 2006. Section 172 requires the Trustees to have regard to the long-term consequences of its decisionmaking on the interests of key stakeholders and to the importance of maintaining high standards of conduct.

In our 2023-2025 strategy we set out the values and strategic aims which inform the Board’s decision-making, reflecting the Board's commitment to the long-term sustainability of SJEHG and to the maintenance of high standards not only in the provision of ophthalmic care and research, but also in governance and in the way we care for our staff. Below we report on how the Trustees engage with four key groups of stakeholders. These are:

  1. Staff

  2. Patients

  3. The Patients’ Communities 4. Donors (including Major Donors and Priories).

The following sections outline a well-established strategy that ensures decisions made by the Board of Trustees are always well informed by our stakeholders. Communications and feedback from our stakeholders are featured in Board meetings and form a fundamental basis for the Trustees’ decisions. Furthermore, Trustees ensure that management operates the Hospital in a responsible manner that reflects the values of The Order of St John.

HOSPITAL STAFF

Within SJEHG there are several staff committees that form the main platforms for decision-making. Each of these committees has at least one Senior Management Team (SMT) representative who is in direct communication with the relevant Trustees.

The Board of Trustees has 14 different specialised committees that meet regularly where SMT members are in attendance. Trustees, working alongside staff representatives, make relevant decisions as appropriate during committee meetings. The Board also meets three times annually: present at Board meetings are SMT members representing the various categories of staff.

Staff surveys are conducted annually to explore staff levels of satisfaction as well as engagement in the decisionmaking process at each Hospital. These findings are presented at the various Board Committees for further analysis and conclusions.

A good example of the Trustees’ full engagement with staff was the Strategic Plan 2023-2025. Several workshops were held at each Hospital operational level to conduct a SWOT analysis and proposed strategic aims and objectives. These strategic aims were presented to the Board of Trustees who, with the SMT, agreed a set of five strategic objectives that shape the Hospital activities throughout the strategy (see p 12).

PATIENTS

As part of our commitment to upholding JCI standards, we are committed to ensuring patients are engaged with Hospital management on a regular basis and that their suggestions for service improvements are taken on board (this is assessed by JCI inspectors). Patients’ views are fully appraised through a biannual survey that is conducted across SJEHG by our quality-of-care teams. Patients are asked to comment on the service they receive as well as to make recommendations for improvements and their perceived needs for additional services as appropriate. The results of these surveys are discussed at the Board of Trustees’ meetings and decisions concerning patients expressed needs are taken by the Trustees and the SMT. We are committed toward achieving equity in our services and we consult with local disability and women’s rights organisations to best understand how we can meet their needs.

PATIENTS’ COMMUNITIES

The Chair and CEO meet with representatives from the Palestinian Ministry of Health at the ministerial level and with NGOs in Palestine to discuss the needs of their patients and strategies that SJEHG might be able to employ to respond to such needs. The SMT is in constant dialogue and communication with representatives from the Israeli Patients’ Fund to discuss services provided by SJEHG to their patients. Decisions

relating to the delivery of services are brought to the various Trustees’ committees for discussion.

The Board of Trustees are fully aware of the considerations and decisions made at the Jerusalem community level. In this regard, we are part of the East Jerusalem Hospitals 70 Network that meets regularly to discuss ways of enhancing the quality of care provided to patients in East Jerusalem. As well as the East Jerusalem Hospitals Network, St John Eye Hospital is a member of the Palestinian Health Cluster Committee which is co-chaired by the WHO. This active engagement with the main healthcare providers in the West Bank and Gaza has been instrumental in identifying patients’ needs and enabling us to coordinate our medical and humanitarian efforts in Gaza, especially after the outbreak of the war.

OTHER MAJOR DONORS AND STAKEHOLDERS

We value the feedback from our stakeholders on what they consider the most effective use of funds and why, and we report back demonstrating the impact of this investment. Our Trusts and Foundations programme have a reporting schedule for every grant given, dependent on each stakeholder’s specific requirements. Our Development Team in Jerusalem is in regular contact with our institutional donors and has a stringent reporting policy for each project managed.

The fundraising Guild of St John

of Jerusalem Eye Hospital is well informed and engaged made up of supporters who work regarding the developments and voluntarily to fundraise for the welfare of their sponsored staff. Hospital. They are a vital channel The Priory in the USA sponsor through which we communicate staff through their Doctor and and receive feedback on our Nurse Initiative and receives work. The organisation is video messages from each staff considered a sub-committee member they support in thanks of the Board (Guild Liaison alongside a more detailed report. Committee) and its membership The US Priory has also sponsored includes, in addition to members the work of our outreach teams. of the Guild, Board Trustees and SMT members. The Guild Various staff members also Chair participates in committee sit on the working groups of meetings which allows us the Johanniter International, a to share information across collaborative organisation aimed Trustees, staff and volunteers, to enable European-based St which feeds into our decisionJohn organisations to develop making. best practice approaches to healthcare, fundraising and Finally, our wider public donors marketing together. Members of are regularly engaged with these teams meet quarterly. via our bi-annual Jerusalem The CEO is in regular with the Scene, our Annual Report, email Priories to keep them informed updates, and our social media about important matters channels. Any donor is welcome regarding SJEHG and the and encouraged to contact our environment in which it works. fundraising team to discuss our work. TRUSTEES

TRUSTEES

Trustees have an involvement PRIORIES in the decision-making and As a foundation member of high-level monitoring of The Order of St John, and material fundraising, project beneficiary of most Priories, development, and marketing. we have a distinct obligation They are all well informed to receive input from and work through regular, timely meetings in collaboration with the wider focused on developments in St John family. We cater our the aforementioned areas. The reporting and engagement to Board, where necessary, give each Priory’s preferences. For input to any donor required preexample, St John Scotland has award surveys or due diligence sponsored both staff and the processes that examine the Mobile Outreach Programme, capabilities, performance and prior to which we provided a policies of SJEHG. detailed report on current and future operation and the budget. The St John Priories in Canada, Australia and New Zealand also sponsor members of staff.

We endeavour to keep Priories

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

30

31

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

----- Start of picture text -----
The Senior Management Team (SMT) of SJEHG
----- End of picture text -----

GOVERNANCE STRUCTURE

Board Committees: SJEHG is a company limited by All committees are chaired by a guarantee in England. The Order trustee to ensure accountability •[Board ] of St John is the sole member to the board. Each committee of the Charity and appoints has the appropriate member(s) •[Steering ] the Chairman of the Board of of the senior management Trustees. The Board manages team in attendance. Each Chair •[Finance ] the business and affairs of SJEHG is required under the terms of and usually meets three times reference to keep membership •[Audit & Risk ] a year, as does the Steering under consideration. Where Committee, with at least one appropriate, committees include •[Investment ] meeting at the Hospital in non-trustee members with •[Clinical Governance ] Jerusalem, where possible. relevant expertise to provide Meetings are held both in person appropriate challenge to the •[Fundraising, Marketing ] and virtually. trustees and senior management. New Trustees are selected by the & Communication The Board reviews the Board to maintain an appropriate •[[Payroll and ]] performance of SJEHG and, in balance of skills, experience and particular, the performance of diversity. Trustees are appointed Remuneration the facilities in Jerusalem, Gaza, for a term of three years and may •[[Human Resources ]] Hebron and Nablus, the Muristan be reappointed for two further and Kufr Aqab, as well as the terms of three years but are not[[Honours & Awards]] Mobile Outreach Programme. normally eligible for a further The Board also considers and reappointment.

No new Trustee was appointed in 2025. One Board member left in 2025. Two new Trustees were appointed in March 2026.

The Board Committees focus, in 2025. Two new Trustees were[Guild Liaison] in detail, on their areas of appointed in March 2026. responsibility and report back Digital and IT to the Board. The Board is aware An induction programme is of the codification of directors’ in place for new Trustees. The Estates & Support Services duties under the Companies Board of Trustees delegates Act 2006 and takes these duties responsibility for the daily The Committee Terms of into account in consideration of management of the charity to Reference were updated SJEHG’s activities and within its the Chief Executive, Dr Ahmad in December 2025 Articles of Association. Ma’ali and the SJEHG senior management team.

THE CHIEF EXECUTIVE

He was also responsible for infection control, acted as clinical services coordinator, and gained a master’s degree in public health management at Al Quds University in 2003. In May 2009, Dr Ma’ali made SJEHG history as the first Palestinian Nursing Director. In 2017, he attained a PhD in Advanced Nursing Practice at De Montfort University and, after 10 years as Director of Nursing and Allied Health Professions, building relations with staff, students and patients, he was appointed as an interim Joint CEO with Peter Khoury in September 2017. In May 2019 Dr Ma'ali became our first Palestinian CEO.

Dr Ahmad Ma’ali

KStJ PhD MPH BSN PGCE ENB

••••••••• CEO Dr Ahmad Ma’ali joined the SJEHG family in 1990 as a student nurse, successfully completing his secondment at Greenwich University in 1996 followed by a six-month postgraduate specialist ophthalmic nursing course at London’s Moorfields Eye Hospital. In 1999, he was certified with a Nurse Tutor Diploma by the Bolton Institute. Thereafter, he returned to Jerusalem where he assumed the role as clinic Charge Nurse for one year, and in 2000 took responsibility for course leadership at the Sir Stephen Miller School of Nursing.

PUBLIC BENEFIT

The public benefits from SJEHG’s activities are:

The Trustees have given due regard to the Charity Commission's General Guidance on public benefit when planning the Charity's activities. Our Annual Report sets out our activities, achievements, and performance during the year, which are directly related to the objects and purposes for which SJEHG exists. SJEHG achieves its principal objectives through the delivery of services to members of the public in Jerusalem, the West Bank and Gaza without regard to ethnicity, religion, social class, or ability to pay.

c. the teaching and training SJEHG’s activities are: activities at SJEHG, which enhance the quality of a. The provision and service delivered and development of clinical and increase the pool of qualified surgical ophthalmic services ophthalmologists, specialist to patients at the hospitals in nurses and allied health Jerusalem, Gaza, Hebron and professionals within the Nablus, the Anabta, Muristan region; and Kufr Aqab Clinics and the Mobile Outreach Programme; d. the research into endemic diseases affecting the b. the exemption of patients' Palestinian population;

charges when the relevant authority does not finance the e. our services enhance treatment, and the patient education and employment is unable to pay all or part prospects and contribute to themselves; economic growth.

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

32 St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

33

TRUSTEES & COMMITTEE MEMBERS

Professor Sajjad Ahmad MBBS FRCOphth PhD

•••

Professor Sajjad Ahmad is a Consultant Ophthalmologist at Moorfields Eye Hospital (London, UK), and Professor of Corneal Regeneration at the Institute of Ophthalmology (University College London) and the Moorfields-UCL NIHR Biomedical Research Centre. Mr Chris Hoult OStJ FCA As well as managing general (Treasurer and Company corneal diseases and cataract Secretary) and refractive surgery, he is best ••••••••••••••••••••• known for his clinical expertise Chris Hoult joined the Board in complex inflammatory ocular of Trustees in January 2022 as surface diseases and ocular Treasurer bringing over 25 years surface reconstruction with stem of board level experience in roles cell therapies. He also runs a lab that have encompassed Finance, group at UCL with a research IT, Procurement, Estates and interest in corneal epithelial healing Facilities as well as international and limbal stem cells. Sajjad joined trading which included two the Board in March 2026. years spent living and working in Denmark. He qualified as a Chartered Accountant in 1987 and since then he has worked in a variety of commercial and not-forprofit organisations including four years as the Director of Finance of Plymouth Hospitals NHS Trust and nine years advising NHS organisations in London on major strategic reorganisation projects. Having spent five years as the Director of Finance of the Royal Voluntary Service up to the end of 2024, he now provides interim support to charities on a range of Mrs Avey Bhatia OBE OStJ RGN, financial and governance matters. MPA

Sir Andrew Cash OBE GCStJ (Chairman)

Prof. David H Verity KStJ, MA (Oxon), MD (Lon), BM BCh, FRCOphth (Order Hospitaller)

•••

Sir Andrew is an experienced Chair, Non-Executive Director and Chief Executive working in the health, life sciences, charity and consultancy sectors. He is Chair of the international Board of Trustees of SJEHG. He is also a Trustee on the Executive Committee of the Order of St John and Chair of the Europe, Middle East and Africa (EMEA) region of the Order of St John. Andrew joined the UK’s National Health Service (NHS) as a fast-track graduate management trainee and was a successful Chair and CEO for more than 35 years. He has worked at local, regional and national levels by invite at the Department of Health on several occasions, most recently as Director General. He has been Chair of an Integrated Care Board, led an integrated care system and was the founder CEO of the Sheffield Teaching Hospitals NHS Foundation Trust from 2004 to 2018.

• •••••••••••••••••••••

Dr David Verity is the Order's Hospitaller and an oculoplastic surgeon at Moorfields Eye Hospital in London. His professional positions include past Treasurer, then President, of the British Oculoplastic Surgery Society, past Treasurer for the European Society (ESOPRS), and previous Editor in-Chief of the international journal ‘ORBIT’. Ten years after its formation, he continues as clinical lead of SJEHG’s Ophthalmic Association, a professional subsidiary of SJEHG which runs local and international teaching programmes, and which introduces healthcare professionals across the world of ophthalmology to SJEHG. As a surgeon, he has undertaken working visits to our hospitals in Jerusalem and Gaza, with a view to supporting further collaborative surgical work in the West Bank and Gaza in the years to come. Dr Verity’s term as a trustee came to an end on June 24, 2025, however he will remain as a Board Observer.

•••

Avey Bhatia is Chief Nurse at Guy’s and St Thomas’ Trust. Avey qualified in 1991, and her clinical experience includes theatres, general intensive care, coronary

care and cardiothoracic nursing. She held various staff nurse and sister posts at hospitals in London before becoming Chief Nurse and Director of Infection Prevention and Control at St George's University Hospitals NHS Foundation Trust in 2017. Avey holds a postgraduate diploma in health services management and a master’s in public administration. She is also the Trust’s Director of Patient Experience, and the executive lead for adults and children’s safeguarding, and for infection, prevention and control. Beyond Guy’s and St Thomas’, Avey is President of the Florence Nightingale Foundation and Honorary Vice President of The Nightingale Fellowship. Avey joined the Board in January 2022.

Dr Suzanne K Freitag OStJ, MD

••

Dr Suzanne Freitag is the Beyond Guy’s and St Thomas’, Director of Ophthalmic Plastic Avey is President of the Florence Surgery at Massachusetts Nightingale Foundation and Honorary Vice President of The Eye and Ear Infirmary and an Associate Professor at Harvard Nightingale Fellowship. Avey Medical School. She received joined the Board in January 2022. her undergraduate degree from Duke University and completed medical school at Thomas Jefferson University in Philadelphia. She completed ophthalmology residency at Wills Eye Hospital in Philadelphia, neuro-ophthalmology fellowship at Johns Hopkins Wilmer Eye Institute, and ophthalmic plastic surgery fellowship at Harvard and Tufts. She is the Emeritus Editor-in-Chief of the journal Orbit. Dr Freitag is actively involved in surgical mission work in Uganda, Miss Helen Dodds Nevis and other locations, and (Helen Forsyth) OStJ has volunteered at St Johns Eye ••••• Hospital in Jerusalem. Dr Freitag Helen Dodds is an international joined the Board in March 2026. lawyer and board member with over 30 years’ experience in the legal and financial services sectors. She is a CEDR accredited mediator and a Senior Honorary Fellow of the British Institute of International and Comparative Law. Helen is currently also a board member of the UK Gambling Commission and a director of LegalUK. Previously she was Global Head of Legal, Dispute Resolution at Standard Chartered Bank, and a non-executive director of the London Court of International Mr Paul Hackwood OStJ Arbitration and of the UK Human ••••• Tissue Authority. She joined the Board in January 2022. Paul Hackwood is the CEO and

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

34

35

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

General Secretary of Toc H, a with The Order of St John for national community development over 40 years as a member of the charity. He is ordained in the Ceremonial Staff and is currently Church of England and a Canon the Sword Bearer. He retired as at Leicester Cathedral. Paul Lay Chair of The Guild Church has extensive experience in Council of St. Lawrence Jewrymanagement and governance next-Guildhall in April 2025. He within the not-for-profit sector joined the Board in 2017. and has held non-executive roles in both the NHS and the Police Service. He previously served as CEO of the Ampleforth Abbey Trust and the Church Urban Fund, where he established the Together Network, supporting communities in deprived areas across the UK, and the Near Neighbours Programme, fostering relationships between faith communities. He has also held the role of Archdeacon of Loughborough. Until recently, Paul was a Trustee of the Henry Mr Timothy Jones OStJ Smith Charity and currently chairs ••••• its Clergy and Projects Group. He Tim Jones is a retired solicitor, joined the Board in January 2022.

Tim Jones is a retired solicitor, a trustee of the Safer London charity and of the National Botanic Garden of Wales. In 2026 he retired as Chair of Trustees of homelessness charity The Connection at St Martin's. Tim was formerly a partner in the law firm Freshfields Bruckhaus Deringer LLP working on a wide range of corporate and commercial projects internationally. He was managing partner of the London office between 2007 and 2011 and worked in the Madrid office between 1994 and 2000. Tim joined the Board in November 2019.

Mr Jamie Ingham Clark KStJ FCA ••••

Jamie Ingham Clark is a Chartered Accountant and pursued a career in the Lloyd’s insurance market, where he had many years’ board experience as either Finance or Compliance Director. He served on the Court of Common Council (the local authority for the City of London) from 2013 and was the Chairman of its Finance Committee until March 2022. He is a Liveryman of the Clothworker’s and Pattenmaker’s Companies Mrs Ismat Levin OStJ JP and is a member of the Knights •••• Templar. Jamie has been involved Ismat Levin joined the Board

as a Trustee in January 2022. Ismat trained and practiced as a solicitor at City law firm Dentons following which she has spent over 30 years as General Counsel for commercial, international growth and technology-led industries listed on NASDAQ or in private equity contexts. She has substantial experience of intellectual property licensing, governance, risk management and regulation. Ismat has served as a committee member for the Royal College of Radiologists (2016- 2020) and on the Board of LXi REIT plc, a real estate investment trust and FTSE 250 company, listed on the London Stock Exchange, as Non-Executive Director between 2022 and 2024 until it was merged with Secure Income REIT plc. Ismat has served as a Magistrate on the North West London Bench since April 2015.

Mr John Macaskill KStJ CA

••••

John has spent the last 44 years in the financial services industry in New York and London. He qualified as a Chartered Accountant in Edinburgh, and upon qualifying moved to London where he worked for five years with Chemical Bank, which transferred him to New York. John worked at Bankers Trust and finally at JP Morgan before starting his own investment bank as one of the founding partners in 2003. John retired his partnership in 2017. John remains President of his family investment firm. He has served on the boards

of the Edinburgh International Festival American Board, and the American Board of the National Museum of Scotland. He currently chairs his village’s Zoning Board of Appeal, is retired from the vestry of his local St John’s church. John has been a member of the Order of St John since 2012 and has served on the Board of Trustees of SJEHG since 2018. In June 2026 John will become Prior of the US Priory of the Order of St John.

Dr David E.I. Pyott CBE, CStJ

••••

Dr David Pyott is the former Chairman and CEO of Allergan Inc. During his tenure, Allergan was transformed from a small eye care business with about $1 billion in sales to a global company, with sales over $7 billion. Dr Pyott is a member of the Board of several U.S. pharmaceutical companies and formerly on the Supervisory Board of Royal Philips. He is Chairman of the Board of Governors of London Business School, a Trustee of the California Institute of Technology, cofounder and Vice President of the Ophthalmology Foundation and is also involved on the Boards of many other U.S. and international eyecare charities. Dr Pyott and his wife, Molly, are Members of the Priory of the USA and stalwart supporters of SJEHG. Dr Pyott joined the Board in October 2020.

Mr Joachim von Einem

•••

Joachim von Einem was a lawyer and notary public in his own office for more than 40 years in Bremen, Germany. He joined the Johanniterorden in 1976 taking over several functions within the order. From 2008 to 2022 he was the Governing Commander of the Hannover Commandery, covering most parts of Northern Germany. Joachim joined the Board in June 2023.

Ms. Helen Winterton

•

Ms. Helen Winterton serves as His Majesty’s Consul-General to Jerusalem, succeeding Ms. Diane Corner OBE. She took up her appointment in December 2024. Ms. Winterton has an extensive diplomatic career, having served as His Majesty’s Ambassador to Tunis from 2021 to 2024. Prior to that, she underwent full-time Arabic language training from 2020 to 2021. From 2018 to 2020, she was the Deputy Director for the Arabian Peninsula in the

Middle East and North Africa Directorate at the Foreign, Commonwealth & Development Office (FCDO). She served as Deputy Ambassador in Cairo 2015 to 2018, and prior to that she was the Deputy Director for the Middle East and North Africa at the Department for International Development (DFID). Earlier in her career, she was Head of the DFID Office in Jerusalem from 2009 to 2012.

CO-OPTED COMMITTEE MEMBERS WHO ARE NOT TRUSTEES

Mr Ken Baksh

•

Ken is an investment consultant with over 45 years’ experience. He was awarded the Service Medal of the Order of St John in 2026.

Mr Thomas E.K. Cerruti Esq,

CStJ

•

Thomas is a corporate lawyer who has served on numerous boards of healthcare, medical research, arts, and educational institutions. He has held board and/or leadership roles in various private foundations and charitable gateways. As a member of the Priory of the USA, he served as a Chapter member for eight years.

Mr Kevin Custis

•

Kevin is a registered trust and estate practitioner, Legal Executive and the chair of the London Central Branch of the Society of Trust and Estate Practitioners (STEP).

Mr Paul Double CVO OStJ

Paul is a barrister and is currently Counsel to the City and UnderSheriff. Previously, he was the Remembrancer at the City of London. He is also one of HM Commissioners of Lieutenancy for the City of London.

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

36

37

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

~~Tree of Hope, Muristan Clinic~~

STATEMENT OF TRUSTEES' RESPONSIBILITIES

Mr Mike Driver CB

•

Mike is a former Civil Servant and held senior roles at His Majesty’s Treasury, Ministry of Justice and Department for Work and Pensions. He is an accountant and was the President of CIPFA in 2020/21. He now holds roles as a Non-Executive Director and Strategy Advisor.

Mrs Anzo Francis MStJ BA (Hons) FCA BFP

•

Anzo is an ICAEW Chartered Accountant, Law Graduate, and Director of Finance of Water and Sanitation for the Urban Poor.

Mrs Sarah Jane Holden CStJ

Sarah-Jane is the Chair of the Guild of St John of Jerusalem Eye Hospital. She has been a member of the Guild for over 30 years and is a former elected Conservator of Wimbledon & Putney Commons.

Mr David Thompson MStJ ACA

•

David is a chartered accountant with many years of experience in the charity sector. He is also a member of the Ceremonial Staff at the Priory of England and the Islands.

Mr Herbert von Bose

Herbert served on the board of SJEHG until June 2023 and is now a committee member. He is a lawyer and joined the Johanniterorden in 1984, serving as chairman of the Brussels Johanniter Group from 2002 to 2012. Since 2014, he has been Governing Commander of the Balley and is responsible for international affairs.

• The Trustees (who are also Make judgments and directors of SJEHG for the estimates that are reasonable purposes of company law) and prudent; are responsible for preparing the Trustees’ Annual Report • State whether FRS 102 (including the Strategic Report) "The Financial Reporting and the financial statements in Standard applicable in the UK accordance with applicable law and Republic of Ireland" has and regulation. been followed, subject to any

• Make judgments and Companies Act 2006. They are estimates that are reasonable also responsible for safeguarding and prudent; the assets of the charitable company and the group and • State whether FRS 102 hence for taking reasonable steps "The Financial Reporting for the prevention and detection Standard applicable in the UK of fraud and other irregularities. and Republic of Ireland" has The Trustees are responsible for been followed, subject to any the maintenance and integrity material departures disclosed of the charitable company’s and explained in the financial website. statements;

Company law requires the Trustees to prepare financial statements for each financial year. Under that law the Trustees have prepared the financial statements in accordance with United Kingdom Accounting Standards, comprising FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland”, and applicable law (United Kingdom Generally Accepted Accounting Practice).

Legislation in the United • Prepare the financial Kingdom governing the statements on the going preparation and dissemination concern basis unless it is of financial statements may inappropriate to presume that differ from legislation in other the charitable company will jurisdictions. In so far as the continue in business. Trustees are aware at the time of approving the Trustees’ Annual The Trustees are responsible for Report: (a) there is no relevant keeping adequate accounting audit information of which the records that are sufficient to charitable company’s auditors show and explain the charitable are unaware; and (b) the Trustees company’s transactions and have taken all the steps that they disclose with reasonable accuracy ought to have taken as a trustee at any time the financial position to make themselves aware of any of the charitable company and relevant audit information and the group and enable them to establish that the charitable to ensure that the financial company's auditors are aware of statements comply with the that information.

Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of the affairs of the charitable company and the group and of the incoming resources and application of resources, including the income and expenditure, of the charitable group for that period. In preparing these financial statements, the Trustees are required to:

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

38

39

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

FUNDRAISING STATEMENT

St John of Jerusalem Eye organisations affiliated with the Hospital Group, as a charity with Order of St John. While we do not income over £1m, is required to directly oversee this fundraising, make a statement regarding we expect it to be conducted its fundraising activities in in accordance with the Code of accordance with the Charities Fundraising Practice. Act 2016.

Complaints are reviewed by the Fundraising Subcommittee of the Board. We have received no complaints during this financial year.

The Trustees’ Annual Report, including the Strategic Report, on pages 3 to 40 was approved by the Trustees and signed on their behalf by:

Both staff and Trustees are made including the Strategic Report, SJEHG is registered with the aware of the Fundraising Code on pages 3 to 40 was approved Fundraising Regulator and of Practice and our own ethical by the Trustees and signed on complies with the Code of fundraising policy. They receive their behalf by: Fundraising Practice. appropriate training, with a particular focus on safeguarding We raise funds from individuals, vulnerable individuals. charities, corporate donors, events, and legacies. This is This year, we have engaged done both directly through a professional fundraising our fundraising team and via consultancy, CCS Fundraising, Sir Andrew Cash, Chairman, approaches made by Trustees. to help expand our donor base St John of Jerusalem Eye In all our communications and and develop a clear strategic Hospital Group relationships, we are committed fundraising plan. While they do Charity no. 1139527 to being open and transparent. not directly fundraise on our Company no. 7355619 behalf, we hold regular monthly A significant number of meetings to review their activity 6 July 2026 donations also come through and progress.

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

40

41

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

INDEPENDENT AUDITORS’ REPORT TO THE MEMBERS OF ST. JOHN OF JERUSALEM EYE HOSPITAL GROUP

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If we identify an apparent material inconsistency or material misstatement, we are required to perform procedures to conclude whether there is a material misstatement of the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report based on these responsibilities.

Independence

REPORT ON THE AUDIT OF THE FINANCIAL STATEMENTS

We remained independent of the group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, which includes the FRC’s Ethical Standard and we have fulfilled our other ethical responsibilities in accordance with these requirements.

OPINION

In our opinion, St. John of Jerusalem Eye Hospital Group’s group financial statements and parent charitable company financial statements (the “financial statements”):

• give a true and fair view of the state of the group’s and of the parent charitable company’s affairs as at 31 December 2025 and of the group’s incoming resources and application of resources, including its income and expenditure, and of the group’s cash flows, for the year then ended;

CONCLUSIONS RELATING TO GOING CONCERN

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the group’s and the parent charitable company’s ability to continue as a going concern for a period of at least twelve months from the date on which the financial statements are authorised for issue.

• have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards, including FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland”, and applicable law); and

With respect to the Trustees' Annual Report and the Strategic Report included within it, we also considered whether the disclosures required by the UK Companies Act 2006 and Charities Act 2011 have been included.

In auditing the financial statements, we have concluded that the trustees’ use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

• have been prepared in accordance with the requirements of the Companies Act 2006.

We have audited the financial statements, included within the Annual Report, which comprise: the Group and Charity Balance Sheets as at 31 December 2025; the Consolidated Statement of Financial Activities (including income & expenditure account), and the Consolidated Cash Flow Statement for the year then ended; and the notes to the financial statements, which include a description of significant accounting policies .

Based on our work undertaken in the course of the audit, the Companies Act 2006 requires us also to report certain opinions and matters as described below.

However, because not all future events or conditions can be predicted, this conclusion is not a guarantee as to the group’s and the parent charitable company’s ability to continue as a going concern.

Strategic Report and Trustees’ Annual Report

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

respect to going concern are described In our opinion, based on the work in the relevant sections of this report. undertaken in the course of the audit the information given in the Strategic REPORTING ON OTHER Report and the Trustees’ Annual INFORMATION Report for the year ended 31 December The other information comprises all of 2025 is consistent with the financial the information in the Annual Report statements and has been other than the financial statements prepared in accordance with and our auditors’ report thereon. applicable legal requirements. The trustees are responsible for the other information. Our opinion on the In light of the knowledge and financial statements does not cover understanding of the group and the other information and, accordingly, parent charitable company and their we do not express an audit opinion environment obtained in the course or, except to the extent otherwise of the audit, we did not identify explicitly stated in this report, any form any material misstatements in the of assurance thereon. Strategic Report and the Trustees’

BASIS FOR OPINION

We conducted our audit in accordance with International Standards on Auditing (UK) (“ISAs (UK)”) and applicable law. Our responsibilities under ISAs (UK) are further described in the Auditors’ responsibilities for the audit of the financial statements section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

In light of the knowledge and understanding of the group and parent charitable company and their environment obtained in the course of the audit, we did not identify any material misstatements in the Strategic Report and the Trustees’ Annual Report.

RESPONSIBILITIES FOR THE FINANCIAL STATEMENTS AND THE AUDIT

Responsibilities of the trustees for the financial statements

As explained more fully in the Statement of Trustees’ Responsibilities, the trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements in accordance with the applicable framework and for being satisfied that they give a true and fair view. The trustees are also responsible for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the group’s and parent charitable company’s ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the group or the parent charitable company or to cease operations, or have no realistic alternative but to do so.

Auditors’ responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors’ report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements

in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below. Based on our understanding of the group and its industry/environment, we identified that the principal risks of non-compliance with laws and regulations related to healthcare standards in Palestine and Jerusalem, and the Charities Act 2011, and we considered the extent to which noncompliance might have a material effect on the financial statements. We also considered those laws and regulations that have a direct impact on the financial statements such as the Companies Act 2006.

resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations or through collusion. A further description of our responsibilities for the audit of the financial statements is located on the FRC’s website at: www.frc.org.uk/ auditorsresponsibilities. This description forms part of our auditors’ report.

Use of this report

This report, including the opinions, has been prepared for and only for the parent charitable company’s members as a body in accordance with Chapter 3 of Part 16 of the Companies Act 2006 and for no other purpose. We do not, in giving these opinions, accept or assume responsibility for any other purpose or to any other person to whom this report is shown or into whose hands it may come save where expressly agreed by our prior consent in writing.

We evaluated management’s incentives and opportunities for responsibility for any other purpose or fraudulent manipulation of the financial statements (including the risk is shown or into whose hands it may of override of controls), and determined come save where expressly agreed by that the principal risks were related our prior consent in writing. to posting of inappropriate journal entries and manipulation of key accounting judgements and estimates. Audit procedures performed by the COMPANIES ACT 2006 engagement team included: EXCEPTION REPORTING

OTHER REQUIRED REPORTING

• Testing journal entries where we identified particular fraud risk criteria. • Testing estimates and judgements made in the preparation of the financial statements for indicators of bias.

Under the Companies Act 2006 we are required to report to you if, in our opinion:

• we have not obtained all the information and explanations we require for our audit; or

• Reviewing minutes of meetings of the Board of Trustees and Board Subcommittees.

• adequate accounting records have not been kept by the parent charitable company, or returns adequate for our audit have not been received from branches not visited by us; or

• Reviewing the terms and conditions of significant contracts and agreements.

• Holding discussions with the branches not visited by us; or trustees and management to identify • certain disclosures of trustees’ significant or unusual transactions remuneration specified by law are and known or suspected instances not made; or of fraud or non-compliance with • the parent charitable company applicable laws and regulations. financial statements are not in • Assessing financial statements agreement with the accounting disclosures, and agreeing these to records and returns. supporting evidence, for compliance with laws and regulations. We have no exceptions to report

• certain disclosures of trustees’ remuneration specified by law are not made; or

We have no exceptions to report arising from this responsibility.

There are inherent limitations in the audit procedures described above. We are less likely to become aware of instances of non-compliance with laws and regulations that are not closely related to events and transactions reflected in financial statements. Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one

David Hagger (Senior Statutory Auditor) for and on behalf of PricewaterhouseCoopers LLP Chartered Accountants and Statutory Auditors London 6 July 2026

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

42

43

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

ST JOHN OF JERUSALEM EYE HOSPITAL GROUP FINANCIAL STATEMENTS

Consolidated Statement of Financial Activities (Including Income & Expenditure Account) for the year ended 31 December 2025

----- Start of picture text -----
Unrestricted Restricted Endowment Total Total
Funds Funds Funds Funds Funds 2024
2025 2025 2025 2025 £000
£000 £000 £000 £000
Notes
Income and Endowments
Income from donations and legacies 3 2,338 5,755 - 8,093 8,919
Income from charitable activities 4 5,388 - - 5,388 4,425
Income from investments 8e 442 117 - 559 573
Total Income and Endowments 8,168 5,872 - 14,040 13,917
Resources Expended
- -
Expenditure on generating funds (754) (754) (585)
-
Expenditure on charitable activities (5,996) (5,451) (11,447) (9,657)
- -
Governance and Other expenditure (217) (217) (185)
Total Resources Expended 5 (6,967) (5,451) - (12,418) (10,427)
Net income before investment gains 1,201 421 - 1,622 3,490
Net gains on investments 8 988 - 266 1,254 757
Net income 2,189 421 266 2,876 4,247
Transfers between funds 14,15,16 315 (315) - - -
Exchange gains on overseas activities 485 - - 485 68
Net Movement in Funds 2,989 106 266 3,361 4,315
Fund balances brought forward at
24,512 695 3,188 28,395 24,080
1 January
Fund balances carried forward at
18 27,501 801 3,454 31,756 28,395
31 December
----- End of picture text -----

ST JOHN OF JERUSALEM EYE HOSPITAL GROUP FINANCIAL STATEMENTS

Balance Sheets

as at 31 December 2025

Fixed Assets
Tangible assets
Investments
Total Fixed Assets
Current Assets
Stocks
Debtors
Cash
Total Current Assets
Creditors: Amounts falling
due within one year
Net Current Assets
Total Assets Less Current Liabilities
Provision for Liabilities
Net Assets
The Funds of the Group and Charity
Restricted income funds
Endowment funds
Unrestricted income funds
Designated funds
Revaluation funds
Othergeneral funds
Unrestricted income funds
Total Group and Charity Funds
Notes
7
8
9
10
11
12
13
16
17
14
15
17
Group
2025
£000
7,676
19,593
27,269
541
2,915
12,353
15,809
(1,007)
14,802
42,071
(10,315)
31,756
801
3,454
11,957
2,306
13,238
27,501
31,756
Restated
Group
2024
£000
6,098
17,921
24,019
664
3,921
9,907
14,492
(987)
13,505
37,524
(9,129)
28,395
695
3,188
10,379
1,316
12,817
24,512
28,395
Charity
2025
£000
28
16,097
16,125
-
52
9,952
10,004
(112)
9,892
26,017
-
26,017
263
3,454
4,309
2,306
15,685
22,300
26,017
Charity
2024
£000
18
14,311
14,329
-
887
7,753
8,640
(50)
8,590
22,919
-
22,919
160
3,188
4,299
1,316
13,956
19,571
22,919

The Charity's net income was £3,098,000 (2024, £3,613,000).

Prior period comparatives for Creditors: Amounts falling due within one year, Creditors: Amounts falling due after more than one year and Provision For Liabilities have been restated. See note 21 for further details. The accounting policies and the notes on pages 46 to 60 form part of these financial statements.

All gains and losses recognised in the year are included in the Statement of Financial Activities. All of the above results are derived from continuing activities.

The accounting policies and the notes on pages 46 to 60 form part of these financial statements.

The financial statements on pages 44 to 60 were approved by the Trustees and signed on their behalf by:

Sir Andrew Cash Chairman, Board of Trustees

Chris Hoult Treasurer and Company Secretary

Company number: 7355619

6 July 2026

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

44

45

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

ST JOHN OF JERUSALEM EYE HOSPITAL GROUP FINANCIAL STATEMENTS

Consolidated Cash Flow Statement

for the year ended 31 December 2025

2025 2024
Notes £000 £000
Net cash infow from operating activities 19 4,441 997
Cash fows from investing activities
Investment income 8e 559 573
Purchase of tangible fxed assets 7 (2,149) (1,679)
Purchase of fxed asset investments 8a (1,089) (797)
Proceeds from sale of fxed asset investments 8a 772 -
Net cash outfow from investing activities (1,907) (1,903)
Net increase /(decrease) in cash and cash equivalents 2,534 (906)
Cash and cash equivalents at 1 January 9,907 10,867
Exchange losses on cash and cash equivalents (88) (54)
Increase / (decrease) in cash and cash equivalents 2,534 (906)
Cash and cash equivalents at 31 December 12,353 9,907

Notes to the Financial Statements for the year ended 31 December 2025

1 Principal accounting policies

statements. Transactions and balances between the Charity and its subsidiary undertakings have been eliminated from the consolidated financial statements. Balances between the companies are disclosed in the notes of the Charity's balance sheet. A separate statement of financial activities, and income and expenditure account, for the Charity is not presented because the Charity has taken advantage of the exemption afforded by section 408 of the Companies Act 2006.

a Basis of preparation

The Group constitutes a public benefit group as defined by FRS102. The financial statements have been prepared on the going concern basis, under the historical cost convention, except for investments which are stated at market value, with items recognised at cost or transaction value unless otherwise stated in the relevant note(s) to these financial statements. The financial statements have been prepared in accordance with the Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland ("Charities SORP (FRS 102)"), the Financial Reporting Standard applicable in the UK and Republic of Ireland ("FRS 102") and the Companies Act 2006.

The Group's objects are the relief of sickness and the prevention and protection of health, in particular expert eye care in Jerusalem and the occupied Palestinian territories and the clinical, teaching and research activities connected therewith.

Going Concern

BACKGROUND

In assessing the going concern position of the charity and the group, the Trustees have produced detailed, yet adaptable, business plans that consider the group’s forecast and projected activities, the related financial budgets, cash flows and liquidity for the period to December 2027, which is a period of at least 12

These financial statements consolidate, on a line by line basis, the results and financial position of St John of Jerusalem Eye Hospital Group (the “Charity”) together with its wholly owned and controlled charitable subsidiary undertakings, St John of Jerusalem Eye Hospital, St John Eye Hospital in Jerusalem (RA), and St John of Jerusalem Eye Hospital Group Ophthalmic Association Limited (together the “Group”). Where a subsidiary has different accounting policies to the Group, adjustments are made on consolidation to apply the Group’s accounting policies when preparing the consolidated financial

months from the date of approval of the financial statements. This assessment period was selected as it aligns to the group’s financial year end, is consistent with its budgeting process and timelines and is a period of at least 12 months from the date of approval of the financial statements.

Based on the group’s cash flow projections, the Trustees have adopted the going concern basis of accounting in preparing these financial statements.

KEY ASSUMPTIONS

The business and financial plans incorporate the following key assumptions:

• Demand for services from patients and the capacity and supply of patient services by the group is budgeted for the same levels of activity during 2025 due to the current unstable political and security situation in the region. No income is assumed to be received from Gaza during 2026;

• Payment by the Palestinian Authority (directly, or indirectly via its own funding sources) of sufficient payments to the group for patient services provided;

SENSITIVITY ANALYSIS

The Trustees have considered the impact on forecast and projected activities, budgets, cash flows and liquidity of a challenging, yet reasonably plausible, downside scenario (sensitivity analysis) such that the key assumptions are not met, or able to be met, in whole or in part.

This comprises:

Under this scenario, SJEHG projects to have sufficient liquidity through the period to December 2027, by implementing minimal mitigating actions.

Nevertheless, the Trustees have sought to identify certain mitigating actions that could be implemented, in order to provide additional liquidity or reduce cash outflows, so as to ensure that SJEHG can maintain sufficient liquidity over the period to December 2027. Such actions include conducting an efficiency exercise throughout SJEHG.

CONCLUSIONS

Having assessed the combination of all these various matters, the Trustees have a reasonable expectation that the charity and the group have adequate resources to continue in operational existence for the period to December 2027, being a period of at least 12 months from the date of approval of the financial statements. For these reasons, the Trustees have adopted the going concern basis of preparation of these financial statements.

Accordingly, these financial statements do not include any adjustments to the carrying amount or classification of assets and liabilities that would result if the charity and the group were unable to continue as a going concern.

b Foreign currencies

The Charity's functional and presentational currency is pounds sterling. Transactions in foreign currencies are recorded at the exchange rate ruling at the date of the transaction. Monetary assets and liabilities at the year end are translated at the rate ruling at the balance sheet date. Results of overseas operations are translated at the average rate for the period and their assets and liabilities at the balance sheet rate. All exchange differences are dealt with in the Statement of Financial Activities. Exchange differences on the translation of the assets and liabilities of overseas operations are included as Other recognised gains/(losses). All other exchange differences are included as incoming resources or resources expended as appropriate. The exchange rate of the Pounds Sterling to the Israeli Shekel at 2025 year-end was 4.29 (2024, 4.5743), while the average rate for 2025 was 4.5461 (2024, 4.7288).

c Income recognition

Donations and other income are recognised in the financial statements on a receivable basis. Grants are recognised when the entitlement to the grant is confirmed. Legacies are recognised when the entitlement arises, being the earlier of the Group being notified of the impending distribution or the legacy being received. Donations in kind are recorded as income when

the resources are received and recorded at fair value. Income from charitable activities is accounted for when earned (i.e. the service is provided to patients). Subsidies and exemptions in respect of medical services provided without charge are shown as a deduction from gross income

d Medical volunteers

The value of services rendered by medical volunteers is not recognised in these financial statements. However, where doctors, nurses or other members of staff are employed by the Group but paid by third parties, the estimated market value of their services is recorded within both income (donations) and expenditure (salaries).

e Resources expended and basis of allocation of costs

Resources expended are accounted for on an accruals basis and have been classified under headings that aggregate all costs related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with use of resources. The irrecoverable value added tax is included with the item of expense to which it relates.

f Costs of generating funds

These include the salaries and direct expenditure costs of the staff who primarily promote fundraising.

g Expenditure on charitable activities

These represent the costs of providing the medical and training services of the hospital and its clinics including both direct expenditure and the associated support cost.

h Governance costs

These comprise costs attributable to the overall management of the Group's affairs and compliance with constitutional and statutory requirements.

i Cash flow

The Charity has taken advantage of the exemption in FRS 102 from preparing a statement of cash flows, on the basis that it is a qualifying entity and the Group cash flow statement included in these financial statements includes the cash flows of the Charity.

j Pension and other end of service costs

The amount charged in the Statement of Financial Activities in respect of pension costs is the contributions payable in the year on an accruals basis in respect of defined contribution and money purchase pension arrangements. Other end-of-service benefits are recognized as they are earned on an undiscounted basis, as the impact of applying the projected unit credit method to the measurement of the liability is deemed immaterial.

k Rentals

The costs in respect of rentals are charged to the Statement of Financial Activities on a straight line basis over the contract period.

The rental cost for the office in London occupied rent free has been computed based on an estimate of arm's length value. No charge is imputed in respect of the Hospital premises in Jerusalem, which the Group occupied rent free until 2015, after which it has paid a nominal rent.

I Taxation

The Charity and each group entity is entitled to certain tax exemptions on income and gains from investments, and surpluses on any activities carried on in furtherance of their primary charitable objectives.

m Tangible assets and depreciation

Cost of tangible assets includes the original purchase price of the asset and the costs attributable to bringing the asset to its working condition for its intended use.

Donated fixed assets are brought into account at an estimate of their market value at the time of acquisition and, thereafter, depreciated on the bases set out below. The costs of minor additions to fixed assets under £500 are expensed in the year in which they are incurred. Impairment reviews are carried out if there is an indication that the recoverable amount of an asset is below its net book value.

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

46 St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

47

ST JOHN OF JERUSALEM EYE HOSPITAL GROUP FINANCIAL STATEMENTS

Notes to the Financial Statements for the year ended 31 December 2025

Depreciation on fixed assets is provided at rates estimated to write off the cost, less estimated residual value, of each asset over its expected useful life on a straight line basis, as follows:

Buildings - 2.5% per annum Building improvements - 10% per annum Medical equipment - 15% per annum Motor vehicles - 20% per annum Other Assets Other equipment - 20% per annum Fixtures and fittings - 6% per annum Computer equipment - 33% per annum UK office fixed assets - 25% per annum

The estimated useful lives of assets are regularly reviewed. On disposal of an item of tangible assets, the difference between the disposal proceeds and its carrying amount is recognised in profit or loss within ‘Other hospital income’ in note 4.

n Investments

Listed investments are stated at market value. Realised gains and losses on investments are calculated as the difference between the sales proceeds and their market value at the start of the period, or subsequent cost. Unrealised gains and losses represent the difference between market values at the beginning and at the end of the period. Income from fixed assets investments is recorded on an accruals basis. Market value for unlisted investments is calculated by the fund managers using underlying financial information.

o Cash at bank and in hand include

Cash at bank and in hand includes time deposits, and certificates of deposit, in addition to cash at bank and in hand held in current accounts with UK, Israeli and Palestinian Banks. Cash equivalents are short-term (maturity of less than 3 months), highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value.

p Stocks

Stocks are determined using the "first in-first out" method and stocks are stated at the lower of cost and net realisable value.

q Funds

Unrestricted funds are funds which are generally available for the Group to carry out its charitable objectives; these include designated funds, which are amounts that have been set aside to finance tangible fixed assets and a number of other projects. General reserves are unrestricted funds available to be used at the discretion of the Board of Trustees for the furtherance of the charitable objectives of the Group and which have not been designated for any other purpose.

Restricted funds are funds which are subject to specific conditions imposed by the donors.

Endowment funds are capital funds where the capital cannot be spent in the normal course of activities, although the income is added to restricted or unrestricted funds depending on the terms of the original endowment.

Transfers between funds represent tangible fixed assets purchased with restricted donations and used for hospital operations.

r Impairment of non-financial assets

At each balance sheet date non-financial assets are assessed to determine whether there is an indication that the asset may be impaired. If there is such an indication the recoverable amount of the asset is compared to the carrying amount of the asset.

The recoverable amount of the asset is the higher of the fair value less costs to sell and value in use. Value in use is defined as the present value of the future cash flows before interest and tax obtainable as a result of the asset’s continued use. These cash flows are discounted using a pre-tax discount rate that represents the current market risk-free rate and the risks inherent in the asset.

If the recoverable amount of the asset is estimated to be lower than the carrying amount, the carrying amount is reduced to its recoverable amount. An impairment loss is recognised in profit or loss.

If an impairment loss is subsequently reversed, the carrying amount of the asset is increased to the revised estimate of its recoverable amount, but only to the extent that the revised carrying amount does not exceed the carrying amount that would have been determined (net of depreciation or amortisation) had no impairment loss ben recognised in the prior periods. A reversal of an impairment loss is recognised in profit or loss.

s Financial Instruments Policy

The group only enters into basic financial instrument transactions and applies section 11 and 12 of FRS 102 in respect of these financial instruments.

Financial assets and liabilities are recognised in the Consolidated Balance Sheet when the group becomes a party to the contractual provisions of the instrument. The net amount is reported in the Balance Sheet when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Financial assets

Basic financial assets, including trade and other debtors and cash and bank balances are initially recognised at transaction price. Such assets are subsequently carried at amortised cost using the effective interest method.

At the end of each reporting period financial assets measured at amortised cost are assessed for objective evidence of impairment. If an asset is impaired the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows. The impairment loss is recognised in profit or loss. If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.

Other financial assets, including investments are initially measured at fair value, which is normally the transaction price. Such assets are subsequently carried at fair value and the changes in fair value are recognised in profit or loss.

Financial assets are derecognised when (a) the contractual rights to the cash flows from the asset expire or are settled, or (b) substantially all the risks and rewards of the ownership of the asset are transferred to another party.

Financial liabilities

Basic financial liabilities, including trade and other creditors initially recognised at transaction price. Such liabilities are subsequently carried at amortised cost using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Creditors are classified as current liabilities if payment

Judgements also include the classification of liquid resources held within the liquidity fund at Cazenove as cash equivalent. The Trustees do believe that there are a number of current threats that have the potential to be unresolved. Threats include: Stalemate in Gaza with continuing IDF/Hamas activity, a war on Israel from Yemen or Iran, a new Intifada in the West Bank, and the collapse of the Palestinian Authority. This might result in movement restrictions between Israel and the West Bank, difficulty accessing the supplies the hospitals rely on, the PA stopping referring patients to SJEHG, the PA ceasing to provide healthcare services, an outbreak in hostilities deters donors of voluntary income as seen in Gaza, and Gaza activity restricted to Phases 1 & 2 for an extended period. This means that the hospital will need large sum of liquid resources to be available to ensure business continuity, and hence, £4.5m of the liquidity fund at Cazenove has been presented as a cash equivalent.

is due within one year or less. If not, they are presented as noncurrent liabilities.

Financial liabilities are derecognised when the liability is extinguished, that is when the contractual obligation is discharged, cancelled or expires.

t Judgements and estimates

The preparation of financial statements in conformity with

generally accepted accounting principles requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of income and expenditure during the reporting period. Although these amounts are based on trustees' best estimates of the amount, events or actions may mean that actual results ultimately differ from those estimates, and these differences may be material. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the change takes place if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

2 Legal status

The Charity was incorporated in England as a company limited by guarantee in August 2010 under registration number 7355619. It is registered as a charity under number 1139527. The registered office is at 4 Charterhouse Mews, London EC1M 6BB. It has no share capital and the liability of each member in the event of winding up is limited to £10.

Estimates: The Group provides against receivables (mainly the Palestinian Authority Debt) by making estimates based on experience regarding the level of provision required to account for potentially uncollectible receivables. Judgements: As at 31 December 2025, the Group still has an impairment loss provision of £1,362k covering the hospital building, medical and other equipment and inventory in the Gaza branch following the War in Gaza which started back in 2023. Accordingly, the Group has recorded a full 100% impairment loss provision against the net book value of these assets. As the building has remained to be one of the few standing buildings in the neighbourhood, the Trustees believe that the building still has an intrinsic value. However, it is clear, and after taking professional advice, based on a value in use basis assessment, that an impairment loss provision should be recorded, and this has been accounted for at 90% of the net book value of the asset.

3 Income from donations and legacies

----- Start of picture text -----
Unrestricted Restricted 2025 Total Unrestricted Restricted 2024 Total
£000 £000 £000 £000 £000 £000
Donations 1,806 5,755 7,561 3,430 4,691 8,121
Legacies 270 - 270 700 - 700
Donations in kind 262 - 262 98 - 98
2,338 5,755 8,093 4,228 4,691 8,919
----- End of picture text -----

Donations in kind include the value of donated tangible fixed assets and medical supplies £205,000 (2024: £41,000). Income from related parties is set out in note 23.

4 Income from charitable activities

come from charitable activities
2025 2024
£000 £000
Outpatient income 2,357 1,942
Surgical income 2,926 2,464
Less: Patient Relief (848) (589)
Netpatient related income 4,435 3,817
Other hospital income 705 301
Rental income,board and lodging 248 307
Total other income 953 608
Total income from charitable activities 5,388 4,425

Patient Relief principally represents subsidies and exemptions to cover the value of medical services rendered when payment is waived by the Group where funding is not available from the relevant authorities and where the patients are unable to pay any balance owing. All of the above income comprises unrestricted funds.

5 Total resources expended

----- Start of picture text -----
Costs of Costs of
Generating Generating Charitable Charitable Governance & Governance &
Funds Funds Activities Activities Other Costs Other Costs Total Total
2025 2024 2025 2024 2025 2024 2025 2024
£000 £000 £000 £000 £000 £000 £000 £000
Personnel costs (note 6) 357 288 6,822 6,242 37 33 7,216 6,563
Recruitment costs 4 2 - - - - 4 2
Medical costs - - 1,923 1,572 - - 1,923 1,572
Establishment costs 87 84 778 611 19 22 884 717
Depreciation (note 7) 7 1 1,035 872 1 - 1,043 873
Office expenses 31 32 213 168 3 4 247 204
Travel and subsistence 71 25 92 67 - - 163 92
Marketing and publicity 162 128 - - - - 162 128
Auditors' remuneration including VAT - - - - 128 111 128 111
Other professional fees 26 22 41 22 17 - 84 44
Legal fees 9 3 20 17 12 5 41 25
Finance costs - - 27 16 - 10 27 26
Foreign exchange differences - - 496 70 - - 496 70
Total resources expended 754 585 11,447 9,657 217 185 12,418 10,427
Support costs included above - - 1,896 1,205 23 32 1,919 1,237
----- End of picture text -----

Total resources expended in 2025 of £12,418,000 (2024, £10,427,000) comprise £6,967,000 (2024, £6,309,000) for unrestricted funds and £5,451,000 (2024, £4,118,000) for restricted funds.

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

48 St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

49

ST JOHN OF JERUSALEM EYE HOSPITAL GROUP FINANCIAL STATEMENTS

Notes to the Financial Statements

for the year ended 31 December 2025

2025
2024
Support costs comprise:
£000
£000
Personnel costs
547
480
Establishment costs
403
322
Depreciation
105
87
Offce expenses
216
171
Travel and subsistence
92
67
Other professional fees
43
23
Finance costs
17
17
Foreign exchange differences
496
70
1,919
1,237
2025
2024
Auditors' remuneration(excludingVAT):
£
£
External audit
99,484
82,814
Other servicesprovided byexternal auditors
4,068
4,536
103,552
87,350

6 Employee information

a Number of employees

The average monthly number of employees, including part time staff, analysed by function during the year was:


ar was:
2025 2024
Medical, nursing and allied health professionals
Support services
Fundraising
Administration
Number
189
48
9
38
Number
175
45
9
36
284 265

b Staff costs

Staff costs
2025 2024
Wages and salaries £000
6,399
£000
5,819
Social security costs
Other pension costs
517
284
436
286
Other related costs/ (income) 16 22
7,216 6,563

c Emoluments of employees

following bands were:

2025 2024
Number Number
£150,001 - £160,000
£140,001 - £150,000
£90,001 - £100,000
£80,001 - £90,000
£70,001 - £80,000
2
-
1
2
2
-
2
1
1
1
£60,001 - £70,000 2 3

£20,000 (2024, £16,000).

ST JOHN OF JERUSALEM EYE HOSPITAL GROUP FINANCIAL STATEMENTS

Notes to the Financial Statements for the year ended 31 December 2025

d Remuneration received by key management personnel

The total remuneration received by the 11 (2024, 11) senior management personnel in managing the operations of the Group amounted to £894,000 (2024, £844,000).

e Pension costs

Pension costs comprise the contributions payable to authorised Israeli money purchase pension schemes in respect of non UK employees and a UK defined contribution retirement benefit scheme in respect of UK based employees.

costs are included in the Balance Sheet in Provision for liabilities (note 13).

7 Tangible assets

a Group

Buildings &
Improvements
Medical
Equipment
Motor
Vehicles
Other
Assets
Total
Cost £000 £000 £000 £000 £000
1 January 2025 9,914 11,853 318 3,513 25,598
Additions 576 847 37 689 2,149
Exchange differences 691 836 24 266 1,817
Disposals - - - - -
31 December 2025 11,181 13,536 379 4,468 29,564
Accumulated depreciation
and impairment
1 January 2025 6,236 9,958 260 3,046 19,500
Charge for the year 281 536 32 194 1,043
Exchange differences 430 691 19 205 1,345
31 December 2025 6,947 11,185 311 3,445 21,888
Net Book Value
31 December 2025 4,234 2,351 68 1,023 7,676
31 December 2024 3,678 1,895 58 467 6,098

b Charity

b Charity
Other
Assets Total
Cost
1 January 2025
Additions
£000
88
17
£000
88
17
31 December 2025 105 105
Accumulated Depreciation
1 January 2025 70 70
Charge for theyear 7 7
31 December 2025 77 77
Net Book Value
31 December 2025
31 December 2024
28
18
28
18

4951

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

50

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

ST JOHN OF JERUSALEM EYE HOSPITAL GROUP FINANCIAL STATEMENTS

Notes to the Financial Statements for the year ended 31 December 2025

----- Start of picture text -----
a Analysis of movements (Group) Bank Listed Analysis of movements (Group) Bank Listed
Deposits Investments Total Deposits Investments Total
£000 £000 £000 £000 £000 £000
Market value at 1 January 2025 2,887 15,034 17,921 Market value at 1 January 2024 2,701 13,619 16,320
Additions 454 635 1,089 Additions 147 650 797
Withdrawals (772) - (772) Exchange differences 39 8 47
Exchange differences 33 68 101 Unrealised gains - 757 757
Unrealised gains - 1,254 1,254 Market value at 31 December 2024 2,887 15,034 17,921
Market value at 31 December 2025 2,602 16,991 19,593
Historical cost at 31 December 2024 2,887 13,307 16,194
Historical cost at 31 December 2025 2,602 14,018 16,620
In 2024, unrealised gains of £757,000 comprise £591,000 for
In 2025, unrealised gains of £1,254,000 comprise £988,000 for unrestricted unrestricted funds and £166,000 for endowment funds.
----- End of picture text -----

In 2025, unrealised gains of £1,254,000 comprise £988,000 for unrestricted funds and £266,000 for endowment funds.

----- Start of picture text -----
||||||||||| |---|---|---|---|---|---|---|---|---|---| |Listed|Listed| |b|Analysis of movements (Charity)|Investments|Total|Analysis of movements (Charity)|Investments|Total| |£000|£000|£000|£000| |Market value at 1 January 2025|14,311|14,311|Market value at 1 January 2024|13,015|13,015| |Additions|554|554|Additions|573|573| |Unrealised|gains|1,232|1,232|Unrealised|gains|723|723| |Market value|at|31 December 2025|16,097|16,097|Market value|at|31 December 2024|14,311|14,311| |Historical cost at 31 December 2025|13,160|13,160|Historical cost at 31 December 2024|12,618|12,618|

----- End of picture text -----

c Listed investments:

Analysis by category of underlying holding and location

----- Start of picture text -----
||||||| |---|---|---|---|---|---| |2025 Group|2025 Charity|2024 Group|2024 Charity| |£000|£000|£000|£000| |Equity investments|- UK|850|850|516|516| |- Overseas|11,361|11,361|6,944|6,944| |Fixed interest securities|- UK|991|991|965|965| |Property Unit Trusts|- UK|751|751|1,010|1,010| |Alternative Investments|- UK|586|586|479|479| |Sterling & Cash Instruments|- UK|4,160|1,558|4,397|4,397| |Others|- Overseas|894|-|723|-| |Market value of listed investments|19,593|16,097|15,034|14,311|

----- End of picture text -----

At 31 December 2025, the following pooled funds represented each more than 4% of the total investment portfolio:

----- Start of picture text -----
|||| |---|---|---| |Group & Charity|2025 %|2024 %| |Fidelity Global Dividend Fund|5.9|6.0| |Vanguard S&P 500 ETF|8.8|9.2| |SPDR S&P 500 UCITS|6.5|5.9| |M&G Japan Fund|5.1|4.9| |Schroder Income Fund|5.4|5.1| |HSBC FTSE All World Index Fund|10.0|10.1| |Schroder WM Global Sustainable Fund|7.9|-| |T.Rowe Global Tech Equity Fund|4.3|-|

----- End of picture text -----

d Bank deposits

e Income from investments

----- Start of picture text -----
|||| |---|---|---| |2025|2024| |£000|£000| |Unrestricted funds|442|445| |Restricted funds|117|128| |559|573|

----- End of picture text -----

ST JOHN OF JERUSALEM EYE HOSPITAL GROUP FINANCIAL STATEMENTS

Notes to the Financial Statements

for the year ended 31 December 2025

f Investment in subsidiaries

The Charity is the controlling member of St. John of Jerusalem Eye Hospital (SJEH), a UK registered charitable company limited by guarantee (Company No.3867950 and Charity No. 1080185) and having no share capital. The liability of each member in the event of winding up is limited to £10. SJEH provides ophthalmic services through a branch in the occupied Palestinian territories.

The Charity owns one £1 share being all the issued shares in SJEH Trading Limited (Company No.12375269) a UK registered company, which has not traded since incorporation.

The Charity is the controlling member of St John of Jerusalem Eye Hospital Group Ophthalmic Association Limited, a UK private company limited by guarantee (Company No.12631428) and having no share capital. The liability of each member in the event of winding up is limited to £1. The company supports the activities of the Charity.

The Charity is also the controlling member of St. John Eye Hospital in Jerusalem (RA) (SJEHJ), an Israeli registered charitable society (No. 580040368), limited by guarantee and having no share capital. SJEHJ provides ophthalmic services from the Jerusalem Hospital and the Mobile Outreach Programme.

The Charity is the controlling member of St John of Jerusalem Hong Kong Foundation Limited, a Hong Kong registered company (No.3045181), which has not traded since incorporation.

SJEH owns two £1 shares being all the issued shares in The St. John of Jerusalem Eye Hospital (Palestine) Limited (Company No.6365210), which has not traded since incorporation.

Summary financial information for the subsidiary entities:

----- Start of picture text -----
St. John Eye St. John of St. John of Jerusalem St. John Eye St. John of St. John of Jerusalem
Hospital in Jerusalem Eye Hopsital Group Hospital in Jerusalem Eye Hopsital Group
Jerusalem (RA) Eye Hospital Ophthalmic Jerusalem (RA) Eye Hospital Ophthalmic
Association Limited Association Limited
2025 2025 2025 2024 2024 2024
£'000 £'000 £'000 £'000 £'000 £'000
Total income and endowments 8,417 4,775 39 8,232 3,088 162
Total resources expended (9,267) (4,168) (39) (8,158) (2,515) (162)
Net (outgoing) incoming resources before other recognised (losses) / gains (850) 607 - 74 573 -
Other recognised (Losses) / gains (30) 545 - 25 77 -
Net movement in funds (880) 1,152 - 99 650 -
Total assets 11,697 8,429 - 10,848 7,039 -
Total liabilities (12,279) (2,108) - (9,034) (1,870) -
Total funds (582) 6,321 - 1,814 5,169 -
-
Restricted income funds 456 82 - 486 49 -
Designated funds 3,259 4,389 - 2,910 3,170 -
Other general funds (4,297) 1,850 - (1,582) 1,950 -
Total funds (582) 6,321 - 1,814 5,169
----- End of picture text -----

Stocks comprise hospital medical stores and supplies all owned by subsidiaries.

----- Start of picture text -----
Group Group Charity Charity
2025 2024 2025 2024
Note £000 £000 £000 £000
Trade debtors 3,981 3,652 - -
Allowance for bad debts 10 b (2,915) (2,790) - -
Net trade debtors 1,066 862 - -
Donations receivable 1,650 2,835 38 864
Prepayments and accrued income 199 224 14 23
Total debtors 2,915 3,921 52 887
----- End of picture text -----

----- Start of picture text -----
Group Group
2025 2024
£000 £000
1 January 2,790 2,784
Additions 680 359
Write off * (573) (359)
Exchange differences 18 6
31 December 2,915 2,790
----- End of picture text -----

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

52 St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

53

ST JOHN OF JERUSALEM EYE HOSPITAL GROUP FINANCIAL STATEMENTS

Notes to the Financial Statements for the year ended 31 December 2025

11 Cash and cash equivalents
Group
Group
Charity
Charity
2025
2024
2025
2024
£000
£000
£000
£000
Cash at bank and in hand
7,853
5,407
5,452
3,253
Cash Equivalent held at liquidityfund
4,500
4,500
4,500
4,500
12,353
9,907
9,952
7,753
12,353
9,907
9,952
7,753
12
**a **
Creditors
Amounts falling due within one year
Restated
Group
Group
Charity
Charity
2025
2024
2025
2024
Note
£000
£000
£000
£000
Trade creditors
498
662
26
3
Taxation and social security
85
102
2
3
Accruals
341
223
84
44
Deferred income 11 b
83
-
-
-
Total creditors
1,007
987
112
50

Prior period comparatives for Creditors: Amounts falling due within one year have been restated. See Note 21 for further details.

b Deferred income Group Group
2025 2024
£000 £000
1 January - 100
Deferred income 113 (96)
Exchange differences (30) (4)
31 December 83 -

Deferred Income represents income received in advance from renting out some of the hospital's properties in Jerusalem.

**13 a ** Provision for Liabilities
2025
2024
£'000
£'000
Restated
Legal Provisions
397
372
Retirement benefts
9,918
8,757
10,315
9,129

Prior period comparatives for Provision for liabilities have been restated. See Note 21 for further details. Legal claim provision represents management's judgment for potential liabilities arising from legal disputes. Accrued retirement benefits mainly represents amounts payable under Israeli law when staff leave the Group's employment. Such amounts are accrued when earned, based on current monthly salaries and periods of service. The balance also includes provident schemes in respect of certain Jerusalem employees and other retirement benefit amounts payable in line with Palestinian law.

b
**c **
Movement in legal provisions
Group
Group
2025
2024
£000
£000
1 January
372
368
Additions
-
-
Exchange differences
25
4
Payments
-
-
31 December
397
372
Movement in the retirement benefts
Group
Group
2025
2024
£000
£000
1 January
8,757
8,498
Additions
907
919
Exchange differences
614
93
Payments
(360)
(753)
31 December
9,918
8,757
Amounts payable within one year
1,707
1,344
Amounts payable after more than one year
8,211
7,413

ST JOHN OF JERUSALEM EYE HOSPITAL GROUP FINANCIAL STATEMENTS

Notes to the Financial Statements for the year ended 31 December 2025

14 Unrestricted income Funds

Group
General reserves
Designated funds
Revaluation reserve
Total unrestricted funds
Charity
General reserves
Designated funds
Revaluation reserve
Total unrestricted funds
Group
General reserves
Designated funds: Tangible fxed assets
Revaluation reserve
Total unrestricted funds
Charity
General reserves
Designated funds: Tangible fxed assets
Revaluation reserve
Total unrestricted funds
Resources
Gains
Expended
& (Losses)
£000
£000
1 January
2025
£000
Incoming
Resources
£000
Transfers
£000
31 December
2025
£000
(5,924)
11
(1,043)
472
-
990
12,817
10,379
1,316
6,334
1,834
-
-
315
-
13,238
11,957
2,306
(6,967)
1,473
24,512
8,168
315
27,501
(708)
242
(7)
-
-
990
13,956
4,299
1,316
2,195
17
-
-
-
-
15,685
4,309
2,306
(715)
1,232
19,571
2,212
-
22,300
Resources
Gains
1 January
Incoming
Transfers
31 December
Expended
&( Losses)
2024
Resources
2024
£000
£000
£000
£000
£000
£000
(5,436)
(143)
9,653
8,743
-
12,817
(873)
76
9,498
355
1,323
10,379
-
726
590
-
-
1,316
(6,309)
659
19,741
9,098
1,323
24,512
(532)
-
(1)
-
-
726
11,205
4,282
590
3,283
18
-
-
-
-
13,956
4,299
1,316
(533)
726
16,077
3,301
-
19,571

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

54

55

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

ST JOHN OF JERUSALEM EYE HOSPITAL GROUP FINANCIAL STATEMENTS

Notes to the Financial Statements for the year ended 31 December 2025

15 Designated funds

----- Start of picture text -----
1 January Incoming Resources Transfers Gains 31 December
2025 Resources Expended & (Losses) 2025
£000 £000 £000 £000 £000 £000
Group
Designated funds 10,379 1,834 (1,043) 315 472 11,957
Charity
Designated funds 4,299 17 (7) - - 4,309
1 January Incoming Resources Transfers Gains 31 December
2024 Resources Expended 2024
£000 £000 £000 £000 £000 £000
Group
Designated funds 9,498 355 (873) 1,323 76 10,379
Charity
Designated funds 4,282 18 (1) - - 4,299
----- End of picture text -----

Designated funds represent amounts that have been set aside to finance tangible fixed assets £7.7m (2024, £6.1m) and a number of other projects. The areas of designation as set by Trustees are:

ST JOHN OF JERUSALEM EYE HOSPITAL GROUP FINANCIAL STATEMENTS

Notes to the Financial Statements for the year ended 31 December 2025

16 Restricted Income Funds

Transfers -
1 January
31 December
2025
2025
£000
£000
Incoming
Resources
£000
Charitable
Activities
£000
Purchase
of Tangible
Fixed Assets
£000
Charity
Staff sponsorship
-
-
Outreach
-
117
West Bank and Gaza facilities
-
10
Other capital projects
86
31
Patient relief
-
1
Income received from endowments
-
-
Other projects
71
98
Others value less in each case than £25,000
3
6
551
307
150
218
5
117
94
3
(551)
(190)
(140)
-
(4)
(117)
(67)
-
-
-
-
(273)
-
-
-
-
Total Charity
160
263
Capital projects
47
60
Service Delivery projects
443
453
Others value less in each case than £25,000
45
55
1,445
55
4,361
11
(1,069)
-
(4,351)
(1)
(273)
(42)
-
-
Total Group
695
801
5,872
(5,421)
(315)
1 January
31 December
2024
2024
£000
£000
Incoming
Resources
£000
Charitable
Activities
£000
Transfers -
Purchase
of Tangible
Fixed Assets
£000
Charity
Staff sponsorship
-
-
Outreach
-
-
West Bank and Gaza facilities
-
-
Other capital projects
30
86
Patient relief
9
-
Income received from endowments
-
-
Other projects
79
71
Others value less in each case than £25,000
98
3
407
96
58
114
29
128
50
86
(407)
(96)
(58)
-
(38)
(128)
(58)
(181)
-
-
-
(58)
-
-
-
-
Total Charity
216
160
Capital projects
1,020
47
Service Delivery projects
44
443
Others value less in each case than £25,000
37
45
968
292
3,527
32
(966)
-
(3,128)
(24)
(58)
(1,265)
-
-
Total Group
1,317
4,819
(4,118)
(1,323)
695

Charity

Group

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

56 St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

57

ST JOHN OF JERUSALEM EYE HOSPITAL GROUP FINANCIAL STATEMENTS

Notes to the Financial Statements for the year ended 31 December 2025

17 Endowment Funds Group and Charity

Endowment Funds
Group and Charity
1 January
2025
£000
Investment
Gains
£000
31 December
2025
£000
American Society of St John: Walsh Bequest
Frost Charitable Trust
Frost Nursing School
Mr. Owen Smith Endowment
The John Swire Foundation Endowment
556
607
574
122
1,329
46
51
48
10
111
602
658
622
132
1,440
3,188
266
3,454
1 January
2024
£000
Investment
Gains
£000
31 December
2024
£000
American Society of St John: Walsh Bequest
Frost Charitable Trust
Frost NursingSchool
526
576
544
116
1,260
30
31
30
6
69
556
607
574
122
1,329
Mr. Owen Smith Endowment
The John Swire Foundation Endowment
3,022
166
3,188

~~These funds represent:~~

ST JOHN OF JERUSALEM EYE HOSPITAL GROUP FINANCIAL STATEMENTS

Notes to the Financial Statements for the year ended 31 December 2025

19

Restated
2025 2024
£000 £000
Net income before investment gains
Investment income
1,622
(559)
3,490
(573)
Depreciation 1,043 873
Decrease /(Increase) in stocks
Decrease /(Increase) debtors
123
1,006
(25)
(1,771)
Increase / (decrease) in creditors 20 (1,260)
Increase inprovisions
Net cash infow from operating activities
1,186
4,441
263
997

Prior period comparatives have been restated. Refer to Note 21 for further details.

20 Financial instruments

Group Group Charity Charity
2025 2024 2025 2024
Financial assets at fair value through statement of
fnancial activities
Investments
£000
19,593
£000
17,921
£000
16,097
£000
14,311

21 2024 Restatement

year ended 31 December 2024 concerning employee retirement benefits and legal claims. Specifically, these liabilities were presented within "Creditors: Amounts falling due within one year" and "Creditors: Amounts falling due after more than one year," rather than being disclosed separately in accordance with the requirements of FRS 102 and the Companies Act 2006.

----- Start of picture text -----
Restated Restated
18 Total Group and Charity Funds Unrestricted Unrestricted Restricted Restricted Endowment Endowment Total Total
Funds Funds Funds Funds Funds Funds Funds Funds
a Analysis by type of asset 2025 2024 2025 2024 2025 2024 2025 2024
and liability (Group) £000 £000 £000 £000 £000 £000 £000 £000
Tangible assets 7,676 6,098 - - - - 7,676 6,098
Investments 16,139 14,733 - - 3,454 3,188 19,593 17,921
Net current assets 14,001 12,810 801 695 - - 14,802 13,505
Provision for liabilities (10,315) (9,129) - - - - (10,315) (9,129)
27,501 24,512 801 695 3,454 3,188 31,756 28,395
Analysis by type of asset
b and liability (Charity)
Tangible assets 28 18 - - - - 28 18
Investments 12,643 11,123 - - 3,454 3,188 16,097 14,311
Net current assets 9,629 8,430 263 160 - - 9,892 8,590
22,300 19,571 263 160 3,454 3,188 26,017 22,919
----- End of picture text -----

Prior period comparatives have been restated. Refer to Note 21 for further details.

2024 have been restated accordingly.

The effects of this correction are as follows:

----- Start of picture text -----
Previously
Stated Restatement As Restated
£000 £000 £000
Creditors: amounts falling due within one year 2,703 (1,716) 987
-
Creditors: amounts falling due after more than one year 7,413 (7,413)
Provision for liabilities - 9,129 9,129
10,116 - 10,116
----- End of picture text -----

Creditors: amounts falling due within one year Creditors: amounts falling due after more than one year Provision for liabilities

22 Trustees' remuneration

The trustees receive no remuneration.

Reimbursement of trustees' expenses for travel, accommodation and flights for 7 trustees (2024, 6) during the year amounted to £65,525 (2024, 21,861).

Donations made by trustees amounted to £13,135 (2024, £3,750).

Charity Trustee Indemnity insurance is provided at a cost of £9,031 (2024, £12,699) to cover the charity, trustees and officers against potential claims and losses.

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

58 St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

59

ST JOHN OF JERUSALEM EYE HOSPITAL GROUP FINANCIAL STATEMENTS

Notes to the Financial Statements

for the year ended 31 December 2025

23 Related parties transactions

The Charity is a wholly owned subsidiary of The Most Venerable Order of the Hospital of St John of Jerusalem (Charity No. 235979, Principal Office: St John House, 3 Charterhouse Mews, London, EC1M 6BB).

The Jerusalem Hospital premises occupied by the Group are owned by The Order of St John and were previously occupied rent free on a full repairing basis. During 2015, the Group signed an agreement with The Order of St John to lease the Hospital in Jerusalem and similarly the Muristan property at peppercorn rent. In the opinion of the trustees, it would be impracticable to place a value on these facilities.

The Group also occupies, on a rent free basis, offices in London owned by The Order of St John. The value of this facility has been estimated at £57,000 per annum based on the rents payable by the external tenants at the complex. This amount is included in the financial statements as a donation in kind.

During the year, the Chairman of the Charity, Sir Andrew Cash, was also a trustee of The Most Venerable Order of the Hospital of St John of Jerusalem.

Donations include amounts received from Priories and Establishments of the Order of St John, which are considered to be related party transactions:

2025 2024
Priory £000 £000
USA 2,403 2,828
England and the Islands 43 65
Scotland 96 146
New Zealand 127 121
Australia 144 139
Canada 63 33
2,876 3,332
2025 2024
Other Members of St. John Family £000 £000
Johanniter Orde in Sweden 69 36
Johanniter Orde in Nederland 2 -
St John Rescue Corps Malta 14 8
The Secretariat of the Alliance of the Orders of St John 6 8
Commandery of Ards in Northern Ireland 8 -
Johanniter-Unfall-Hilfe in Austria 19 -
118 52
2025 2024
Donations bythe Prioryof the United States: £000 £000
Hospital - General Support 1,519 2,145
Hospital Restricted Gifts 884 683
2,403 2,828

Outstanding donations from the Priories and Establishments of The Order of St John at 31 December 2025 amounted to £977,000 (2024: £877,000).

24 Contractual & designated obligations

In 2025, the Board approved a plan to renovate the hospital theatre at our Gaza Hospital. The total cost for this project was £94k and completed in March 2026.

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

60 St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

61

ST JOHN OF JERUSALEM EYE HOSPITAL GROUP

PROFESSIONAL ADVISERS & ADMINISTRATIVE INFORMATION

London & Registered Office

(a UK Company Limited by guarantee, Company number 3867950), Charity number 1080185); St John Eye Hospital in Jerusalem (RA) (an Israeli charitable society, registration number 580040368) and St John of Jerusalem Eye Hospital Group Ophthalmic Association Limited, a UK Company Limited by guarantee, Company number 12631428).St John of Jerusalem Eye Hospital Group Ophthalmic Association Limited, a UK Company Limited by guarantee, Company number 12631428).

Investment Managers

4 Charterhouse Mews London EC1M 6BB

Schroders (C.I.) Limited PO Box 334, Regency Court Glategny Esplanade St Peter Port Guernsey GY1 3UF

Jerusalem Hospital

2 Mujir Eddin Street Sheikh Jarrah P.O. Box 19960 Jerusalem 91198

Independent Auditors

Savannah House, 3 Ocean Way, Southampton SO14 3TJ

Bankers in the UK

National Westminster Bank Plc 134 Aldersgate Street London EC1A 4JB

St John of Jerusalem Eye Hospital Group (a UK Company Limited by guarantee, Company number 7355619, Charity number 1139527) has three subsidiary undertakings; St John of Jerusalem Eye Hospital

Bankers in the occupied Palestinian territories

Bank of Palestine PLC Hebron Road P.O. Box 765

Bethlehem

----- Start of picture text -----
Hebron Outreach,
November 2025
----- End of picture text -----

ST JOHN PRIORY FUNDING 2025

£ $

£144k Australia, £63k Canada, £43k England and the Islands, £127k New Zealand, £96k Scotland, £2.4m USA

THANK YOU

Without our donors we could not continue to save sight and change lives. The patients and staff at SJEHG greatly appreciate the support of everyone who has given or helped in some way in 2025. The St John Priories from around the world have, once again, delivered much-valued assistance to SJEHG and we thank them for their continued support.

We are grateful to the Guild of St John of Jerusalem Eye Hospital, the St John Ophthalmic Association, the Friends of St John Society, the Alliance of the Orders of St John, St John Associations and the St John Fellowship for their on-going and crucial support.

~~A total of 1,827 hours were offered by volunteers in 2025 (compared to 1,095 in 2024). We thank volunteers for their time provided to support our work.~~

The Fred Hollows Foundation German Federal Foreign Office Johanniter International Assistance (JIA) The Knights Templar Martin & Esmee Clarke Charitable Trust Maybach Group Ltd. Middle East Children’s Alliance (MECA) Palestine Children’s Relief Fund (PCRF) Qatar Fund for Development (QFFD) – State of Qatar Roche Products Ltd

FURTHER MAJOR DONORS 2025:

American Near East Refugee Aid (ANERA) Arab Fund for Economic and Social Development Australian NGO Cooperation Program (ANCP) Australian Representative Office, Ramallah The British Humane Association CARE International

CBM International

Champalimaud Foundation Christian Broadcasting Network (CBN) The Clothworkers’ Foundation The David and Molly Pyott Foundation Department of Foreign Affairs and Trade (DFAT), Australia

The Saïd Foundation

UK-Med

United Nations Development Programme (UNDP) United Nations Office for Project Services (UNOPS) United States Agency for International Development (USAID) via Jhpiego World Health Organization (WHO) And to all our anonymous donors

The Dumetum Trust

The Edwina Mountbatten & Leonora Children’s Foundation

European Society of Cataract and Refractive Surgery (ESCRS)

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

62

63

St John of Jerusalem Eye Hospital Group Trustees’ Annual Report and Financial Statements 2025

If you would like to support St John of Jerusalem Eye Hospital Group or would like more information, please contact us:

4 Charterhouse Mews, London EC1M 6BB, United Kingdom +44 (0)20 7253 2582 info@stjohneyehospital.org

2 Mujir Eddin Street Sheikh Jarrah P.O.Box 19960 Jerusalem 91198

www.stjohneyehospital.org

@stjohneyehospital

@StJohnEyeHosp @StJohnEyeHospital